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This work is dedicated to my mother and father, for without 
their love and support it would never have been completed. 
ABSTRACT 
Oxygen sensitive drugs in aqueous solutions are very 
susceptible to oxidative degradation. Antioxidants are 
frequently used to protect these drugs from oxidation. A 2-
level resolution VI factorial was used to evaluate a glucose 
oxidase-catalase~glucose system and . compare it to commonly 
used aqueous antioxidants. The drug models used to test the 
effectiveness of the enzyme system were ascorbic acid, 
morphine sulfate, and isoproterenol hydrochloride. 
The glucose oxidase system successfully protected the 
isoproterenol hydrochloride and was significantly better than 
the other systems tested. The glucose oxidase system was just 
as effective as the other antioixidants in protecting morphine 
sulfate. None of the systems tested were deemed satisfactory 
for ascorbic acid. 
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Chapter I. Introduction 
It is important that pharmaceutical products be stable 
for a reasonable length of time. If a pharmaceutical 
preparation changes during storage, such change may well 
affect its usefulness and safety. These changes can be 
harmful in two primary ways. First, the pharmaceutical 
product may los.e potency over time, until at some point, the 
product will fail to perform adequately, resulting in 
therapeutic failure. The second harmful event that can occur 
is the appearance of toxic products in the preparation due to 
degradation of the preparation. It is possible for both 
events to oc·cur in a single pharmaceutical product. These 
possibili ties imply legal, moral, and economic reasons to 
protect drug products from decomposing. (1,2,3,4) 
Fortunately, the formation of toxic degradation products is 
extremely rare, but loss of potency over time is the rule 
rather than the exception. It is for these reasons that 
stability data and expiration dating are mandated by· the FDA, 
in both the New Drug Application (NDA), and the Current Good 
Manufacturing Practices (CGMP) regulations 211.166 and 
211.167. (5,6,7) 
The breakdown of pharmaceutical products is chemical in 
2 
nature and occurs at definite rates. There are several 
pathways by which active ingredients in pharmaceuticals may 
degrade. These include oxidation, hydrolysis, racemization, 
decarboxylation, ring cleavage, photolysis, and 
microbiological degradation. (8,9,10,11,12) The rates of these 
reactions depend on conditions such as concentration of 
reactants, temperature, pH, light, and the presence of 
catalysts. Most pharrnaceuti~al degradations are zero-order, 
first-order, or pseudo-first-order, or can be treated as such, 
even though the actual mechanism may be quite complex. (13) 
Chapter II. Background 
2.1 OXIDATION 
Theoretically, any organic compound can oxidize, (14) and 
oxidation is a major source of product instability. Examples 
of drugs susceptible to oxidative degradation are given in 
Table 1.(15,16,17,18,19) 
The definition of oxidation has been refined and expanded 
over time. Lavoiser originally described it as combination 
with oxygen, hence the term, oxidation. Today oxidation is 
thought of as the addition of oxygen, the loss of hydrogen, or 
the loss of electrons, with or without the loss of a proton. 
(20,21,22) The primary characteristic of oxidation is the 
loss of electrons. (23) Oxidation is a complimentary reaction 
with reduction. When one substance is oxidized, another is 
reduced. (24,25) The classical inorganic redox system can be 
described by Equation 1: 
reduced form ~ oxidized form + n electrons Eqn. 1 
where n is the number of electrons transferred in the process. 
4 












































Vitamin D reduced 
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An electron donor and an electron acceptor are integral 
to an oxidative process. The substance with the greatest 
tendency to lose electrons is oxidized, and it reduces the 
other substance(s). The tendency to lose electrons is 
quantified as the electromotive force (EMF). 
When some sUbstance A is oxidized 'to product 'B, the 
change in free energy is described by 
AG = AGo + RT In ( B) b / (A) a Eqn. 2 
where AG is the free energy change of the entire reaction, dGo 
is the free energy of the standard reaction, R is the gas 
constant, T is absolute temperature, (A) and (B) are the 
activities of the reactants A and B, respectively, and a and 
b are the number of moles and A and B, respectively. From 
thermodynamics it is known that 
AG = -nFE Eqn. 3 
and 
Eqn. 4 
where n is the number of moles of the reacting substance, F is 
the Faraday constant, E is the EMF of'the reversible 
electrochemical cell, and EO is the EMF of the reversible 
electrochemical cell at standard state. 
If Equations 3 and 4 are substituted into Equation 2, the 
following is obtained: 
-nFE = -nFEo + RT ln (B) b / (A) a Eqn. 5 
6 
This can be rearranged to give 
E = EO - (2. 303 RT /nF ) -1og ( B ) b / (A) a Eqn. 6 
which is the Nernst equation (26). 
2.1.1 MECHANISM OF ACTION 
The overall mechanistic ,understanding of oxidation 
reactions is poor. This is due to the complexity of oxidative 
degradation, and the fact that these reactions are so greatly 
influenced by trace amounts of catalysts. This makes 
reproducibility extremely difficult. This problem is 
exacerbated in pharmaceutical dosage forms due to the usual 
multicomponent nature of these systems. (26) The stoichiometry 
of a reaction may be as simple 
RH + 02 -+ ROOH Eqn. 7 
but the kinetic law may not necessarily be as simple as 
d[ROOH]/dt = k[RH][02] Eqn. 8 
The medium also has an important influence on these 
reactions. A good example of medium influence lS the 
oxidation of hydroquinone (1, 4-dihyroxybenzene) to its quinone 





However/ in an aqueous medium/ free electrons do not exist. 





This reaction is further complicated by the fact that the 
quinone can catalyze the oxidation further. This process is 
called product catalysis or autocatalysis. (27) 
2.1.2 AUTOXIDATION 
Oxidations undergone by almost all pharmaceutical systems 
are autoxidations. Autoxidation is a radical chain reaction 
between molecular oxygen and organic compounds at low or 
moderate temperatures. (28) 
2.1.3 CYCLIC PEROXIDE THEORY 
Modern theories of autoxidation are dated from around 
1900 to the work of Bach and Engler and coworkers. They 
studied the role of organic peroxides in slow oxidation, and 
introduced the term "activated oxygen". They argued that 
autoxidation was molecular rather than atomic in nature. They 
8 
theorized that a molecule of oxygen added at the double bond 
to from a peroxidized compound, R,-O-O-R2' and that this 
compound could, in turn oxidize other compounds. 
Fahrion, and later, Ellis, working with linseed oil 
postulated the formation of a cyclic peroxide 
R,-CH-Q R,-CH-oH RI-CH-QH • I I ..... I . I Eqn. 9 
R2-CH-:-O Rz-C-oH R2-C=O 
2.1.4 ETHYLENE OXIDE THEORY 
Fokin, in 1909, proposed a theory in which the first step 
in the autoxidation of an ethylenic bond was the formation of 
an ethylene oxide ring 
H H 




While epoxy compounds have been isolated from autoxidation 
mixtures, it is now considered doubtful that they are primary 
products. 
2.1.5 HYDROPEROXIDE THEORY 
Farmer and his coworkers are due the major credit for 
9 
developing the hydroperoxide hypothesis of autoxidation. 
According to Farmer, almost all unconjugated olefinic 
compounds autoxidize by a chain reaction involving addition of 
a molecule of oxygen to the carbon atom adjacent to the double 
bond, forming an intact hydroperoxide having an intact double 
bond 
-CH2-CH=CH- + O2 ~ -CH(OOH)-CH=CH- Eqn. 11 . 
This may not be the primary step, but it is the main chain-
reaction propagating step.(29) 
2.2 KINETIC FEATURES 
It should not be surprising that autoxidation is a free 
radical process, since the oxygen molecule is a diradical 
... . . 
. 0:0 .. Alkanes, alkenes, alcohols, aldehydes, and ethers are .. .. 
all susceptible to autoxidation by· the same general process. , 
This process involves hydroperoxide formation 
RH + O2 .... ROOH Eqn. 12 
There are three steps in the chain reaction process. 
They are as follows: 
1. initiation 
2 . propagation 
3. termination 
The total process is summarized by the following reactions: 





In· + RH ~ R· + InH 
R· + O2 ~ ROO· 
ROO· + RH ~ R- + ROOH 





ROO· + R· 
R· + R· 
stable products Eqn. 18 
stable products Eqn. 19 
INITIATION 
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Ini tiation reactions are triggered by singlet oxygen, 
~xcited states of photosensitizers, heavy metals, radiation, 
environmental pollutants, or the addition of radical initiator 
such as azonitrile and peroxides. Initiation results in free 
radical formation. 
2.2.2 PROPAGATION 
The propagation phase is the phase in. which the chain 
reaction occurs. The free radical, R-, can react with an 
oxygen molecule to form a new radical species, ROO-. This 
peroxy radical, ROO-, can react with a molecule of RH to from 
a peroxide, plus a new radical, R·, which can start the cycle 
over. This can theoretically proceed until all the oxygen or 
• 
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RH is consumed, although this rarely happens. 
2.2.3 TERMINATION 
Most free radical reactions, while very efficient, rarely 
continue until one of the components is consumed, because the 
radicals tend to react with one another. This often breaks 
the chain, because many of the products formed are stable. 
Looking at equations 14, 15, and 16, 
In- + RH ~ R- + InH 
R- + O2 ~ ROO-
ROO- + RH ~ ROOH + R· 
and simplifying equation 14 slightly gives 
initiator 
ROO· + RH 
k' 1 
-+ R-
The termination equations are then 
ROO· + ROO- . stable products 
Eqn. 14 
Eqn. 15 





ROO- + R- stable products Eqn. 24 
R- + R- stable products Eqn. 25 
If we let k2[R-] [02] = k3[ROO·] [RH], and k4 = ks = k6 = kt , 
assuming normal levels of oxygen, and applying a steady state 
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assumption to the radical species ROO· and R·i the rate of 
hydroperoxide formation is described by 
d[ROOH]/dt = (ri/kt )" k3 [RH] (k2(02]/ (k3 [RH] + k2 (021» Eqn. 26 
where r i is the rate of initiation and k t is the termination 
rate constant. 
From this equation it is obvious that the hydroperoxide 
formation rate is proportional to the square root of r i • If 
,oxygen concentration is very high, that is, k2[02]»k3 [RH], 
then Equation 26 simplifies to 
d[ROOH]/dt = (r;/k t >"k3 (RH] Eqn. 27 
This reaction is apparent first order with respect to material 
concentration [RH]. If, however, k3[RH]»k2[021, then the 
equation simplifies to 
d[ROOHJ/dt = (r i /kt >"k2(02] Eqn. 28 
This reaction is pseudo~zero-order with respect to the 
[RH], and first-order with respect to [02]. If r i involves RH 
or O2, the order of the reaction with respect to RH and O2 
could be as high as 1.5.(30,31,32). 
2.3 PEROXY RADICALS 
Pharmaceutical products I which are primarily organic 
substances, are subj ect to autoxidation I which is a free 
radical mediated process. A free radical is defined as a 
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molecule or atom with one or more impaired electrons. (33) The 
peroxy radical is the cornman thread in most pharmaceutical 
deqradative oxidations. 
Peroxy radicals react with a wide variety of molecules, 
The primary reactions with molecules are as follows: (34) 
1. hydrogen atom abstraction 
2. addition to unsaturated systems 
3. radical displacement 
4. oxygen atom transfer 
2.4 HYDROGEN ATOM ABSTRACTION 
The rate constant of free radical hydrogen atom 
abstraction depends first and foremost on the activation 
energy of the reaction. oxidations involving Equation 16 will 
be fast if the O-H bond formed (ROO-H) is at least as strong 
as the R-H bond which is broken. Peroxy radicals tend to be 
strongly resonance stabilized. ROO-H bond strength has been 
estimated to be around 90 kcal/mol. This means that this bond 
is stronger. than an allylic or benzylic bond, which is around 
84 kcal/mol. Resonance weakened O-H, S-H, and N-H bonds of 
phenols, thiophenols, and aromatic amines provide readily 
abstractable hydrogen atoms. 
ROO- is a relatively unreactive radical. It is this 
14 
relative unreactivity that makes ROO· very selective in its 
hydrogen abstraction from hydrocarbons. It has a strong 
preference for the most weakly bound hydrogen atom. While the 
R-H bond strength is the most important factor determining the 
rate constant for hydrogen abstraction from RH, steric and 
polar factors can also have a significant effect. 
2.5 ADDITION 
Mayo and coworkers have contributed most of the knowledge 
of the addition mechanism of oxidation. They have shown that 
some readily polymerizable or copolymerizable olefins (e.g., 
styrene, a-methyl styrene , and methyl methacrylate), yield 
mainly a 1:1 copolymer of oxygen and olefin. 
ROO- + C=C -+ ROOCC· Eqn. 29 
ROOCC- + O2 -+ ROOCCOO· Eqn. 30 
The peroxy radical always adds to the double bond in such a 
way as to produce the more stable ~-peroxy alkyl radical 
Eqn. 31 
When the double bond is conjugate with an aromatic, carbonyl, 
ni trile, or another· vinyl group, addition is favored over 
abstraction of an allylic hydrogen. 
2.6 RADICAL DISPLACEMENT 
15 
Organoboron compounds autoxidize by a free-radical chain 
reaction which, as shown in Equation 32, most likely involves 
a radical displacement on boron as one of the propagation 
steps 
ROO- + B~ -+ [ROOB- R3 ] -+ ROOB~ + R- Eqn. 32 
Other alkyl derivatives of group III metals also react readily 
with oxYgen. This most likely occurs by the same type of 
mechani~. In addition, Grignard reagents probably oxidize by 
a free-radical pathway which may be a displacement reaction. 
2.7 OXYGEN ATOM TRANSFER 
A rapid chain reaction autoxidation which involves oxygen 
atom transfer is that of trialkyl phosphites and trialkyl 
phosphines which is shown as follows: 
ROO· + P(OR)3 -+ [ROOP- (OR)3 1 -+ RO- + OP(OR)3 
ROO- + P~ -+ (ROOp· R3 ] -+ RO- + OPR3 
2.8 OTHER REACTIONS 
2.8.1 ELECTRON-TRANSFER REACTION 
Eqn. 33 
Eqn. 34 
Some carbanions readily autoxidize. Examples include the 
oxygen absorption of triphenylmethane· (pKa = 2.8) and 
diphenylrnethane (pka = 3.0) in basic dimethyl sulfoxide 
solution. The rates of oxygen absorption are equivalent to 
16 
the rates of ionization of the hydrocarbons. The reactions 
correspond kinetically to the simple fast addition of oxygen 
to the carbanion. 
slow 
RH + B- R:- + HB Eqn. 35 
fast 
Egn. 36 
Reaction 36 is probably a two step process 
Eqn. 37 
With more acidic hydrocarbons, such as fluorene (pKa = 
2.1) or 9-phenylfluorene (pKa = 1.6), the reaction involves 
the carbanion in equilibrium with the hydrocarbon 
fast 
~ R:- + HB Egn. 38 
slow 
~ Eqn. 39 
For 2-nitropropane chain propagation occurs by electron 
transfer from the carbanion to the peroxy radical in basic 
solution 
R:- + ROO· ~ Eqn. 40 
This reaction does not occur in the absence of'catalysis. 
Transition metals such as manganese and cobalt are 
usually noted for catalyzing autoxidation of organic 
sUbstances. However, at high concentrations, these metals 
sometimes act as inhibitors. This is probably due to chain 
17 
termination by electron-transfer reactions. (36) 
ROO· + Mn3+ ~ ROO· + Mn2+ Eqn. 41 
Eqn. 42 ROO- + Co3+ ~ ROO· + co2+ 
2.9 PROTECTION FROM OXIDATION 
Complete protection of pharmaceutical products subj ect to 
oxidative degradation is impossible, but there are a. number of 








A summary of these methods is as follows: 
2.9.1 
Temperature control 
Protection from light exposure 
pH adjustment 
Avoidance/removal of trace metals 
Re~oval of atmospheric oxygen 
Addition of antioxidants 
TEMPERATURE CONTROL 
As with most chemical reactions, 
temperature will increase reaction rates. 
the necessary energy to start a reaction. 
an increase in 
Heat may provide 
A general rule of 
thumb is that for every 10 0 increase in absolute temperature, 
oxidation rates increase two to three times. A complicating 
factor in oxidation rea'ctions is that" while decreasing 
temperature will decrease reaction rates, it also increases 
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dissolved oxygen content in aqueous systems. Therefore, any 
stabili ty gain from temperature control may be offset by 
increasing dissolved oxygen concentration. (37,38,39) 
2.9.2 PROTECTION FROM LIGHT EXPOSURE 
oxidation reactions can be triggered by exposure to 
certain frequencies of light. Examples of photosensi ti ve 
drugs include epinephrine, prednisolone, hydrocortisone, 
prednisone, paraldehyde, vitamins A and D, ergometrine, and 
riboflavin. Photochemical reactions are of tw.o types. In the 
first, the absorbing molecule decomposes. In -this type of 
reaction, the bonds absorbing the light are ruptured. In the 
second, the energy is transmitted to another molecule which 
then decomposes. Photolysis plays a role in oxidative 
reactions by providing the energy necessary to start the 
initiation phase of the reaction. It does so by creating the 
free radicals necessary to start the chain. Drugs can be 
protected from photolytic degradation by exclusion of all 
light by storage in opaque containers, or by exclusion of the 
particular wavelengths which trigger the reaction, by use of 
appropriately pigmented glass.(40,41,42,43,44,45) 
2.9.3 pH ADJUSTMENT 
The effect of hydrogen ion concentration (i.e., pH), 
must be considered in some redox reactions. When hydrogen ion 
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concentration is a factor, it can be explained by the Nernst 
equation. 
E = EO -[(RT/nF) In (ox)/(red)] - (RT/nF) In [H30+] Egn. 43 
This can be reduced to 
E = EO - (RT/nF) [(In (ox)/(red» - pH] Egn. 44 
Therefore I as pH increases I the oxidation potential increases. 
Lowering th~ pH of the system, for many oxygen sensitive 
drugs, stabilizes the system, increasing the resistance to 
oxidation. (46,47,.48) 
2.9.4 TRACE METALS 
Oxidation reaction rates can be· dramatically increased 
due to the presence of heavy metal contamination. Heavy metal 
ions such as Fe3+, cu2+, c03+, Ni 2+, and Mn3+ all can act as 
radicals that initiate the free radical chain processes. 
Metal ions do this by a number of ways. They can react 
directly with oxygen, they can form a complex with oxygen and 
subsequently form a peroxy radical, or the metal ion can react 
with the drug itself to form a radical as shown below 
M"+ + RH -+ M(n"1)+ + H+ + R- Eqn. 45 
Metal ions can also react with a hydroperoxide in the system 
M"+ R I OOH -+ M(n·1)+ + H+ + R' 00· Eqn. 46 
R'OOH can be a hydroperoxide of the drug itself or some other 
component or contaminate of the formulation. (49,50,51) 
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Since these metal ions can catalyze oxidation reactions, 
they are obviously undesirable in" pharmaceutical preparations 
subject to such degradation. There are two ways to deal with 
this problem. The first is avoidance of their introduction 
into the preparation. Use of distilled water, stainless 
steel, or non-metallic containers, especially glass can 
greatly reduce metal ion contamination. secondly, agents can 
be added to the preparation which prevent these ions from 
catalyzing the reactions. These agents, often referred to as 
synergists, are chelating agents. 
Chelating agents, also known as complexing agents, or 
sequestering agents act by binding metal atoms, removing them 
(thermodynamically) from the system. They reduce lability 
wi th regard to electron transfer. In general, when one 
valency state of a metal ion becomes very stable by 
complexing, the reactions involving oxidizing and reducing 
radicals will be inhibited. This results in a decrease of 
free radical carriers. In fact, the metal may act as a chain 
terminator when complexing of the higher valency state affects 
the redox potential to such an extent that the ROO- radical 
will react with the metal ion in its lower valency state in 
preference to reacting with the autoxidizing substrate. Heavy 
metal catalysts (unless present in such complex forms as 
porphyrin derivatives) will have their lability with regard to 
electron transfer reactions between valency states reduced by 
21 
complexing with organic hydroxy acids such as citric acid, 
malic acid, and tartaric acid. Similar effects are obtained 
with salts of ethylenediamine tetraacetic acid (EDTA). These 
salts are the most commonly used chelating agents in 
pharmaceutical products. Figure 1 shows an example of the 
complexing of calcium ions by the tetrasodium salt of EDTA. 
(52,53,54,55) 
• 
2.9.5 REMOVAL OF ATMOSPHERIC OXYGEN 
oxidation· reactions are mediated by free radicals or 
molecular oxygen, which is itself a diradical. Oxygen can add 
to a molecule and give peroxy radicals. It. also can act as an 
oxidant (i.e., an electron acceptor). These two possibilities 
are· illustrated below 
· RH + 02 ..... HROO· Eqn. 47 
Eqn. 48 
Since atmospheric oxygen can play a role in catalysis of 
oxidation, and in many case is extremely important in the 
propagation phase of autoxidative reactions, it would seem to 
follow that exclusion of oxygen would prevent these reactions. 
In fact, it is almost impossible to completely remove oxygen 
from a drug delivery system, and depending on the dosage form, 
may not be practical or' possible. However I for delivery 





Complexing Agent + Metal Ion ~ Metal Complex + Sodium Ions 
From L. Lachman, Drug Cosmet. Ind, 43-45, 146-149, Feb 
1968. 
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systems such as ampuls, reduction of oxygen content by 
nitrogen sparging, nitrogen head filling, or evacuation can be 
useful in slowing oxidative degradation. Liquids can be 
deoxygenated by nitrogen sparging or boiling. Solids can be 
hermetically sealed in strip packages. 
(56,57,58,59,60,61,62,63,64) 
2.9.6 ANTIOXIDANTS 
The last step in protecting a drug from oxidation is the 
addition of antioxidants. These are agents that inhibit 
oxidation, enhancing stability and palatability of tbe 
product. 
2.10 CLASSIFICATION OF ANTIOXIDANTS 
Antioxidants are frequently classified by their mechanism 
of action. For example, Shotton divided antioxidants into two 
categories as follows: 
1. ,Reducing agents 
2. "True antioxidants" 
Reducing agents are substances which are themselves 
oxidized by combining with any oxidizing agents present. 
Examples include the water soluble anions such as sulfite, 
nitrite, and ascorbate. 
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The "true antioxidants" are substances which 
preferentially react with atmospheric oxygen/ thus protecting 
the drug from a similar reaction. These substances are 
effective in low concent.rations. (65) 
Antioxidants are frequently divided into four categories 
as follows: 
1. metal sequestering agents 
2. reducing agents 
3. preferential oxidation 
4. free radical acceptor/chain terminator 
These mechanisms of action will now be discussed in more 
detail. The role of'metal sequestering agents has already 
been discussed. 
2.10.1 REDUCING AGENTS 
These are generally not used. Since oxidation and 
reduction are complimentary reactions, the concept is to add 
agents which will reduce the oxidized drug back to its reduced 
form. There is no guarantee that this strategy will work. 
Ascorbic acid and sodium thiosulfate have been used as 
reducing agents. (66) 
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2.10.2 PREFERENTIAL OXIDATION 
This type of antioxidant undergoes oxidation instead of 
the drug it is to protect. They also act as oxygen 
scavengers. Ascorbic acid and sulfurous acid salts are good 
examples of oxygen scavengers. 
sulfite is shown as follows: 





so .. · + M· 3 
so -. 
5 
S032- + HSOs- -+ HS04- + S04
2- (pH :s 7) 
S032-. + SOs2- -+ 2S04







SOs-· + Inhibitor - Non-reactive products Eqn. 56 
The inhibitor in reaction 56 can be any number of compounds, 
both organic and inorganic, including alcohols, glycerin, 
mannitol, acetaldehyde, and phenol. 
In theory, it would seem to be a simple matter to choose 
antioxidants to protect drug systems in this manner by simply 
choosing an antioxidant that has a higher oxidation potential. 
In reality this is often very difficult. 'It can be difficult 
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to determine the redox potential of a complex system. The 
redox potential is a good starting point, but only systematic 
stability testing can confirm the effectiveness of a chosen 
antioxidant. (67 ,68,69,70,71,72,73,7.4,75) Table 2 shows some 
drug and antioxidant oxidation potentials. 
2.10.3 FREE-RADICAL ACCEPTOR/CHAIN TERMINATORS 
since oxidation is a radical chain process, interrupting 
the chain should slow the oxidation process. Interrupting the 
chain process in the propagation phase can result in 
significant decreases in oxidation rates. ' 
R· + O2. ..... ROO-
ROO· + RH ..... ROOH + R· 
Addition of an antioxidant, AH, results in the following 
scheme: 
R· + AH ..... RH + A· Eqn. 57 
ROO- +AH ..... ROOH + A· Eqn. 58 
A- + RH ..... no reaction Eqn. 59 
A· + A· ..... A-A Eqn. 60 
A·+ R- ..... AR Eqn. 61 
The radical A· is stable, and thus incapable of continuing the 
chain reaction. That is 
R- + AH ..... negligible Eqn. 62 
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Table 2 
Standard Oxidation Potentials for Some Drugs and Antioxidants 
(E· corresponds to (reduced) ~ (oxidized) + e-) 
Substance E~ IV pH Temperature, ·c 
Riboflavin +0.208 7.0 30 
Di thiothrei tol +0.053 7.0 30 
Thiourea +0.029 7.0 30 
Ascorbic acid +0.003 7.0 2-5 
Sodium metabisulfite -0.114 7.0 25 
Sodium bisulfite -0.117 7.0 25 
Acetylcysteine -0.293 7.0 2,5 
Vitamin K -0.363 20 
Epinephrine -0.380 7.0 30 
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Peroxy radicals are the dominant ones. 
These antioxidants lose a hydrogen free-radical or an 
electron. The functional groups of these antioxidants are 
(-OH), (-SH), or (-NH). The O-H , N-H, and S-H bonds are weak 
enough to release the hydrogen, but not so weak as to favor 
too rapid reaction, which would result in quick consumption of 
the antioxidant. (76,77,78,79) 
2.11 KINETICS 
Backstrom was the first to demonstrate antioxidants act 
by providing an alternate pathway to the chain propagating 
process and are themselves oxidized. (80) Bolland and ten Have 
did the first kinetic investigation in light of the present 
hydroperoxide theory of chain propagation. The system used in 
these investigations was ethyl linoleate containing benzoyl 
peroxide and ethyl linoleate hydroperoxide as initiators, and 
hydroquinone as the inhibitor. 




-+ R· Eqn. 20 
R· + O2 
k2 
-+ ROO· Eqn. 21 
ROO· + RH ROOH + R· 
ROO· + ROO· stable products 
stable products 
k6 
R· + R· ~ stable products 
and at high oxygen concentration 
ru = -d[02]/dt = d[ROOH]/dt = (ri/kt)~k3[RH] 







In the presence of the inhibitor AH, Bolland and ten Have 
postulated that the following two reactions would lead to 
inhibition of the chain reaction 
ka 
ROO· + AH ~ products Eqn. 63 
ka ' R· + AH ~ products Eqn. 64 
stationary state methods then lead to the following rate 
equation: 
ra = -d[02]/dt = (r i k3[RH]/[AH]) (k2[02]/(k2ka[02] + 
k3ka' [RH] + kaka' [AH] ) ) Eqn. 65 
where ra is the rate of oxygen uptake in the presence of the 
antioxidant, AH. 
Experimental evidence indicated that reaction 64, 
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R· + AH ~ products 
did not occur to a significant extent. This means Equation 
65 can be simplified to 
r. = -d[021/dt = r i k3 [RH]/k2[AH] Eqn. 66 
This is valid if the initial radicals formed are 
hydroperoxides I ROO-. If I however, the initial radicals 
formed are R· I then the rate equation would be 
Eqn. 67 
At low inhibitor concentrations the difference between these 
two equations is not great.(81,82) 
The kinetics of the destruction of the inhibitor, 
hydroquinone I were also examined. The scheme for chain 
termination by hydroquinone gives the following equation: 
-d[AH]/dt = ri/n Eqn. 68 
where n is the number of chains terminated by one hydroquinone 
molecule. Combining Equation 68 with Equation 66 gives 
-d[ROOHJ/d[AH] = nk3 [RHJ/k2[AH] Eqn. 69 
If [RH] is assumed to remain constant, i.e., neglecting 
the change in (RH] over a short period of time, it can be 
derived by integration that 
In [AH]o - In [AH] = (k3/nk2) ([ROOH] - [ROOH]o> / [RH] Eqn. 70 
The rate equation implies that ra varies as l/[AH], so the 
term In [AH]o - In [AH] is the same as In (ra ) - In (ra)o' 
where (ra ) is the current rate of hydroperoxide formation, and 
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(r.)o the initial rate of hydroperoxide formation, and 
therefore: 
In (r.) = In (r.)o + (k3/nk2 [RH]) ([ROOHl - [ROOH]o) Eqn. 71 
Plotting In (r.) against '([ROOHl - [ROOH]o) gave Bolland 
and ten Have a straight line. This was considered confirm-
ation of the postulated reaction mechanism. 
2.12 OTHER FACTORS IN CHOOSING AN ANTIOXIDANT 
There are factors other than mechanism of action which 
must be considered before choosing an antioxidant. Lachman 
summarized the properties of an ideal antioxidant as follows: 
1. Stable and effective over a wide pH range 
2. Soluble in its oxidized form 
3. Oxidized form and its reaction compounds should be 
colorless 
4. Non-toxic and non-irritating 
5. Stable during manufacture and sterilization by 
heating 
6. Soluble in selected concentrations in particular 
system 
7. ~ompatible with closures and containers 
8. Compatible with components in solution 
9. Effective at low concentrations 
1~. Chemically inactive with other constituents of 
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preparation 
11. Be non-volatile 
since no antioxidant currently exists which meets all these 
requirements, the antioxidant chosen must be the best 
compromise that will do the job. Table 3 summarizes the most 
common pharmaceutical antioxidants in use today. (83) Figure 
2 shows the structures of some of these antioxidants. 
2.14 PROBLEMS WITH ANTIOXIDANTS 
Antioxidants are not a panacea for oxidation problems. 
Antioxidants will not completely protect a substance from 
oxidation. They provide virtually no protection if added 
after the oxidation is well under way. A product must be 
appropriately packaged and some combination of the techniques 
previo~sly described must be used 
protection to the product. (84) 
to provide maximum , 
There is no method currently available to accurately 
evaluate and especially to predict antioxidant effectiveness 
beforehand in any individual system. compounds possessing 
higher standard oxidation potentials than the drug being 
protected may not be effective over the long term. 
Accelerated stability test results must be cautiously 
interpreted in light of temperature dependent solubility 
changes. (85) 
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The system in which the antioxidant is to be used imposes 
limitations 'on which antioxidants may be used. The pH of a 
system is very important in selection of appropriate water 
soluble antioxidants. For example, the sulfites, the most 
common antioxidants in water soluble systems, have distinct pH 
stability ranges. Sodium bisulfite is most effective between 
pH 1 to 5, as is sodium metabisulfite. sodium sulfite, on the 
other hand, is more stable and effective at a solution pH of 
7 to 10. Sodium thiosulfate is unstable at acidic pH. Other 
antioxidants affected by solution pH include acetylcysteine, 
cysteine, and thioglycol which all are more stable and 
effective at acidic pH.(86) 
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Toxici ty of antioxidants is a critical concern. Toxic effects 
for many antioxidants have been reported at higher 
concentrations. There are also questions about possible 
carcinogenicity of BHA, BHT, and ,TBHQ. The sulfites also 
have toxicity problems, and have been increasingly under 
attack. Recently the sulfi tes have lost their GRAS (Generally 
Recognized As Safe) status for raw vegetables. (87,88,89) The 
thiol derivatives tend to have objectionable odors. Thiourea 
may be carcinogenic. (90) 
Another major problem with the sulfites, which are the 
most commonly used antioxidants in water soluble systems, is 
their reactivity with the systems they' are meant to protect. - . 
Some of the drugs which sulfites have been reported to 
interact with include epinephrine, isoproterenol, thiamine, 
ephedrine, and morphine. (91,92) The reactivity of bisulfite 
with drug molecules can be predicted on the basis of known 
reactions between various functional groups. These reactions 
include the following: 
1. Compounds containing reactive carbonyl groups react 
with bisulfite to form hydroxysulfonic acids 
2. Formulations containing alkene linkages may react 
with bisulfite to yield sulfonic acids 
3. Aromatic nitro compounds react with bisulfite to 
form arylamino sulfonic acids 
4. Alkyl halides react with sulfite to yield alkyl 
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sulfonic acids.(93) 
2.15 GLUCOSE OXIDASE 
Glucose oxidase was first described by Muller in 1926 
from the press juice of Aspergillus niger, and later 
Penicillium glaucum. He demonstrated that the enzyme 
catalyzed the oxidation of glucose to an acidic product he 
identified as gluconic acid. (94) In 1937 I Francke and Lorenz, 
using a more highly purified preparation, found that hydrogen 
peroxide was formed in the reaction. They suggested that the 
enzyme was a flavoprotein.(95) 
Coulthard and coworkers succeeded in preparing a highly 
pure form from Penicillium notatum. They named the enzyme 
notatin. (96) Van Brugger and coworkers independently purified 
the same enzyme, calling it penicillin B. They suggested that 
the prosthetic group was the alloxazine-adenine 
dinucleotide. (97) Kielin and Hartree confirmed that the 
enzyme was , in fact, a flavoprotein, and that the prosthetic 
group was alloxazine-adenine dinucleotide (riboflavin-
phosphate-phosphate-ribose-adenine), conventionally termed 
flavin adenine dinucleotide (FAD). They concluded that 
glucose oxidase, notatin, and penicillin B were the same 
enzyme. (9a) 
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Bentley and Neuberger showed that the enzyme is an 
oxidoreductase, formerly called P-D-glucopyranose 
aerodehydrogenase. The Enzyme Commission designation is P-D-
glucose: oxidoreductase E. C. 1.1.3.4. For convenience it will 
continue to be referred to as glucose oxidase. Bentley and 
Neuberger's research demonstrated that the oxygen consumed is 
dissolved oxygen and not from the water molecules. The enzyme 
catalyzes the transfet of hydrogen from glucose to oxygen. 
This reaction is shown in Figure 10, where the enzyme is 
represented by P-FAD.(99) 
The industrial grade product contains catalase as well, 










2.15.1 USES OF GLUCOSE OXIDASE 
Glucose oxidase has been used for several purposes. Due 
to its specificity for glucose it has been used to estimate 
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this sugar. Kielin and Hartree first proposed this use in 
1947.(101) It is used by millions of people on a regular 
basis as a component of home tests for glucose in urine in 
Testape and Cl~nistix. In this system a piece of paper is 
impregnated with glucose oxidase, peroxidase, and o-tolidine. 
The strip is. moistened with the urine to be tested and if 
. glucose is present the following reactions will occur: 
glucose 
glucose + oxygen ~ 
oxidase 
peroxidase 
H20z + o-tolidine ~ oxidized o-tolidine 
(blue color) 
The test is sensitive down to 0.1% glucose. (102) 
Eqn. 75 
Eqn. 76 
Glucose oxidase is also used in the food industry. It is 
used to desugar egg albumin and whole eggs prior to drying. 
This prevents the development of off-flavors and is easier to 
control than bacterial or yeast fermentation. (103) 
The ability of a glucose-glucose oxidase system to remove 
oxygen has been used to protect a variety of food and. 
beverages from flavor and color changes, as well as preventing 
can corrosion from acid canned foods. (104) It is used to 
protect beer from spoilage. It has been shown to protect 
unpasteurized beer from spoiling at room temperature for up to 
fifty days. Unpasteurized beer, if unprotected, will spoil in 
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seven to twelve- days at room temperature, and in thirty days 
if refrigerated. (105) 
Glucose oxidase has been used to protect mayonnaise, (106) 
dry whole milk and dry ice cream mix,(107) animal feeds,(108) 
and strawberry products. (109) A number of patents describe 
the use of packets containing glucose oxidase-glucose systems 
to protect foodstuffs. (110) 
One unique patent describes the use of a glucose oxidase-
glucose-catalase system impregnated on porous igneous rocks 
and used to preserve and cakes, breads, -and optical 
instruments. (111) Similar patents include those of Scott and 
Scott and Hammer. (112) 
Glucose oxidase has also been used to remove trace oxygen 
from agar for growing anaerobes. (113) There is one Japanese 
patent for a pharmaceutical use. Taisho Pharmaceutical 
Company, Ltd. holds a patent for stabilizing an aqueous 
vitamin A product. (114) 
2.15.2 SUMMARY OF GLUCOSE OXIDASE PROPERTIES 
Glucose oxidase is a glycoprotein. (115) It is a 
multichain (subunit) enzyme. (116) The molecular weight has 
been reported to be between 150,000 and 186,000 daltons. Most 
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recently, a molecular weight of 160,000 for the holoenzyme, 
and 80,000 for the apoenzyme has been reported. (117) The 
carbohydrate content has been reported to be 16 to 19% of the 
molecule. (11S) Tables 4 and 5 show the reported constituents 
and amino acid composition of the enzyme. (119) Glucose 
oxidase has two molecules of bound flavin (FAD) per molecule 
of protein. (120) The FAD is bound by adenine, ribose, 
phosphate, and dimethylisoalloxazine. (121) The FAD is tightly' 
bound and stabilizes the three dimensional structure of the 
enzyme. Swoboda proposed that the protein exists mainly with 
the molecular conformation of a loose, flexible coil. On the 
addition of FAD, the protein is converted to a compact, nearly 
spherical form possessing enzyme activity. (122) 
Glucose oxidase is active over a fairly wide'pH range, 
with good activity between pH 2 and 8. The pH optimum has 
been reported to be S.6 and 6.5. Figures 3 and 4 show the pH 
dependence of glucose oxidase. (123) Glucose oxidase is 
unstable at pH's above 8, although the presence of glucose has 
been reported to have a stabilizing effect. ( 124 ) The dry 
enzyme is stable for two years at O°C, and eight years at'-
15°C. It is rapidly inactivated at temperatures above 60°C. 
Figures 5 and 6 show the effects of temperature on glucose 
oxidase activity. (12S) 
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TABLE 4: CONSTITUENTS OF GLUCOSE OXIDASE 
CONSTITUENT % (BY WEIGHT) 
Protein 74.0 ± 2.8 
Neutral sugar 16.4 ± 0.3 
Amino sugar 2.4 ± 0.5 
Metal (ash) -0.4 
FAD 0.9 
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TABLE 5: AMINO ACID COMPOSTION OF GLUCOSE OXIDASE 
AMINO ACID G AMINO ACID NUMBER OF AMINO 
RESIDUES/100 RESIDUES/MOLE 
G PROTEIN ENZYME 
Lys 3.31 30 
His 3.90 34 
Arg 5.51 42 
(NH3 ) 2.51 174 
Asp 12.02 124 
Thr 6.83 80 
Ser 5.48 74 
Glu 10.55 96 
Pro 2.37 28 
Gly 6.52 136 
Ala 5.62 94 
Val 5.25 62 
Met 2.89 28 
lle 4.53 48 
Leu 10.00 104 
Tyr 4.87 36 
Phe 3.87 32 
Trp 3.36 22 
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Glucose oxidase is highly substrate specific. It 
oxidizes ,B-D-glucose almost exclusively. It will very slowly 
oxidize D-galactose, D-mannose, and D-xylose.(126) The 
oxidation-reduction potential has been reported to be Eo = 
0.080 ± 0.010 V. (127) The isoelectric point has been 
variously reported to be 4.2 and 4.3 to 4.5.(128) 
The reaction mechanism of glucose oxidase oxidatio~ has 
been postulated by Nakamura and Ogura (129) to be 
Eqn. 77 
Eqn. 78 
where Eox represents the oxidized form of the enzyme, Ered the 
reduced form, Eox·S the 'enzyme (oxidized form)-substrate 
complex, S is the substrate, and P the product. 
Massey, and Swoboda (130) have suggested that it is 
Gibson, 
E + S ~ E ed- P ~ E ed + P ,ox r r Eqn. 79 
~qn. 80 
where Ered·P and Eox·H202 represent the enzyme (reduced form)-
product and enzyme (oxidized form)-hydrogen peroxide 
complexes, respectively.(131) Chan and Bruice have suggested 
that rather than a two electron process, the oxidation occurs 
through a radical intermediate. (132) 
:~ 
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Chapter III. Objectives 
The objectives of this study were three-fold. The first 
objective was to determine if a glucose oxidase/glucose system 
could be effecti ve as an antioxidant in an aqueous pharm-
acetical system. The second objective was to compare such a 
system to currently available antioxidant systems. The third 
objective of this study was to compare combinations of 
antioxidants, including combinations with glucose oxidase. 
The initial experiments were to determine if the glucose 
oxidase system would rapidly remove oxygen from an aqueous 
solution. These experiments utilized an oxygen probe. Three 
model drugs were then selected to determine the effectiveness 
of a glucose oxidase system and compare it to typical 
antioxidants. This was done using half and full-fraction 
factorial designs. The use of a factorial design allowed 
comparison of individual antioxidants and combinations of 
antioxidants. 
Chapter IV. Experimental 
4.1 MATERIALS 
4.1.1 GLUCOSE OXIDASE PRELIMINARY EXPERIMENTS 
Glucose Oxidase Miles KBA5C261 
Dextrose Fisher 850753 
Boric Acid Baker 33077 
Potassium Matheson Coleman NA 
Chloride and Bell 
Sodium Hydroxide Mallinckrodt NA 
Distilled water NA NA 
.... '" ... 
i".·e./ 'i:·}I:)~()~t~]~::~·l1Inl?e··l ·t· .... >. (where" 
orion en Electrode Model 97-08 
orion Meter Model 811 
Corning Hot Plate/Stirrer Model PC-35l 
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4.1.2 ASCORBIC ACID AMPUL FILL 
I;.II~I! •. '[i~III,I,lit .• ' lilll,~·'···'···'·~ 
:0: 7C'.11 ;~~~III 
:::::::::.' .:":~.::':':.'''<: .•. ;,;;:·::::: .. : .. ·::::···:::····:·:·:····U:·[ 
::; :: .. :{;.:.~::::.,,:::: 
.. >:: ••... :.:::.,:c ~:: 
Ascorbic Acid Fisher 872999 
Sodium Bisulfite Aldrich 61810CT 
Sodium Aldrich D5 20015AP 
Metabisulfite 
N-acetylcysteine Fisher 871253 
Thiourea Fisher 871104 . 
Glucose Oxidase Boehringer 10438026-07 
Mannheim 
Dextrose Fisher 850753 
Sodium Phoshate Matheson Coleman SX 720 
and Bell 
Sodium Hydroxide Mallinckrodt NA 
Sodium Sulfite Matheson Coleman SX 790 
and Bell 
Distilled Water NA NA 
NitLuy,::u Gas NA NA 
5 mL Amber Ampuls Owens-Illinois NA 
Type 1 
Cozzoli Ampul Filler F400X 
Cozzoli Ampul Sealer HS1 
NAPCO Incubator 3512 
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4.1.3 ASCORBIC ACID BOTTLE FILL 
;: " 
Ascorbic Acid Fisher 871253 
Sodium Bisulfite Aldrich 01810CT 
Sodium Aldrich 20015AP 
Metabisulfite 
N-acetylcysteine Fisher 871253 
Thiourea Fisher 871104 
Glucose Oxidase Boehringer 10438027-07 
Mannheim 
Dextrose Baker 500997 
Distilled water NA NA 
NAPeo Incubator 3512 
4.1.4 MORPHINE AMPUL EXPERIMENT 
J~' 
11!1.:~" .. :·: 
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4.1.5 MORPHINE AUTOCLAVE EXPERIMENT 
Mallinckrodt CBV H 386021 
Sodium Bisulfite Aldrich 01810CT 
N-ace teine Fisher 974425 
Thiourea Fisher 871104 
Glucose Oxidase Boehringer 10438033-07 
Mannheim 
Dextrose Baker 50-99-7 
Sodium Sulfite Coleman Matheson SX 740 
and Bell 
Distilled water NA NA 
5 mL Amber Owens-Illinois NA 
Ampuls, Type 1 
Cozzoli Ampul Filler F400X 
Cozzoli Ampul Sealer HS1 
AMSCO steam Autoclave 3512 
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4.1.6 ISOPROTERENOL AMPUL EXPERIMENT 
.................. · ... ·.M.·.·t)t~~I...i ...... i ...... ·..... .. 
Isu~Luterenol Sigma 95F-0324 
Sodium Bisufite Aldrich 01810CT 
N-acetylcysteine Fisher 871253 
Thiourea Fisher 871104 
Glucose oxidase Boehringer 10438034-07 
Mannheim 
Dextrose Baker 502354 
Sodium Sulfite Matheson Coleman SX 790 
and Bell 
Distilled Water NA NA 
Cozzoli ......... u .... L.l.l Filler F400X 
Cozzoli 1 Sealer HS1 
NAPCO Incubator 3512 
56 
4.2 METHODS 
4.2.1 GLUCOSE OXIDASE PRELININARY EXPERIMENTS 
All reagents and materials used were A. c. s. analytical 
reagent grade with the exception of glucose oxidase, which was 
an industrial grade. All materials were used as supplied. 
A stock solution of pH 8.5 buffer was prepared using the 
method described in the U. S. P., Volume XIX, p. 654. A 
solution was made by dissolving 25.9858 g boric acid and 
29.8423g potassium chloride in distilled water in a 2 L 
volumetric flask and bringing to volume. This solution was 
then adjusted to pH 8.5 with sodium hydroxide. This solution 
was then used to make dextrose solutions of the concentrations 
tested. This was done by accurately weighing the appropriate 
amount of dextrose to make a concentrated s'olution of dextrose 
desired and dissolving the dextrose in the buffer solution in 
a volumetric flask and bringing it to volume. Enzyme 
solutions were prepared by dissolving 1 g of glucose oxidase 
in distilled water in a 100 mL volumetric flask and bringing 
to volume. Dextrose/buffer and buffer were then pipetted to 
a 250 mL Erlhenmeyer flask. The total volume of the two 
solutions equaled 200 mL. The flask was placed on a magnetic 
stirrer and the oxygen probe was inserted and allowed to 
equilibrate. The zero time oxygen level was then recorded and 
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1 mL of enzyme solution was pipetted into the flask and the 
fall in oxygen concentration was followed with the oxygen 
probe. 
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4.2.2 ASCORBIC ACID AMPUL FILL 
Ascorbic acid solutions were prepared by dissolving 
ascorbic acid in distilled water to make a stock solution 
containing 100 mg/mL ascorbic acid. This solution was then 
used to prepare solutions containing the individual 
antioxidants tested. The antioxidant stock solutions were 
prepared by accurately weighing the individual antioxidant 
and transfering it to a 100 mL volumetric flask. The 
antioxidant was then dissolved in the ascorbic acid stock 
solution and brought to volume. The antioxidant solutions 
prepared were 4 times the final concentrati.on and these 
solutions were then used to prepare the appropriate final 
concentrations by pippetting 25 mL of antioxidant solution to 
a 100 mL volumetric flask. Glucose oxidase solutions were 
prepareq by dissolving the contents of 2 containers 
(SO/OOOu/container) in ascorbic acid stock solution in a 100 
mL volumetric flask and bringing to volume. Each antioxidant 
solution was added to a flask in such a way as to make the 
combinations called for by the factorial design used. The 
flask was then brought to volume (if necessary) with the 
ascorbic acid solution. All volumetric flasks and pipetes 
used were Class A. All reagants used were A. C. S. reagant 
grade with the exception of glucose oxidase, which was an 
industrial grade provided by Boehringer Mannheim Biochemicals. 
The final concentrations of each antioxidant is as follows: 
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Sodium bisulfite 0.5 mg/mL 
Sodium metabisulfite 1.0 mg/mL 
Acetylcysteine 5.0 mg/mL 
Thiourea 1.0 mg/mL 
Glucose Oxidase 250 u/mL 
Glucose 50 mg/mL 
Each antioxidant was present at the level indicated 
above, or absent as dictated by the two-level factorial shown 
in section 4.4, Figure 14. These stock solutions were then 
used to fill 5 rnL, amber, Type 1 ampules (Owens-Illinois), 
using a Cozzoli ampul filler. 
The solutions containing nitrogen were made in the same 
way, except nitrogen was .bubbled through the distilled water 
before the addition of the ascorbic acid. The volumetric 
flasks used to prepare the stock solutions were purged with 
nitrogen before using, and a nitrogen head was put on each 
volumetric flask after the stock solutions where prepared. 
Ampules were purged with nitrogen before filling, and nitrogen 
was bubbled through the solutions before sealing. A nitrogen 
head was put on each ampul before sealing. Ampuls were heat 
sealed using a Cozzoli ampule sealing device. The ampules 
were then placed in an incubator (NAPeO) at 45°C. Ampules 
were removed periodically from the incubator and assayed by 
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HPLC as described in section 4.3.1. This experiment was 
discontinued because of extreme ampul to ampul variability. 
The formulation of each run is shown in Table 6. 
RUN ASCORBIC N2 BISULfITE 
ACID 
1. 100 HG/HL 
2. 100 HG/HL YES 
3. 100 HG/HL 0.5 HG/ML 
4. 100 HG/ML YES 0.5 MG/HL 
S. 100 HG/ML 
6. 100 HG/ML YES 
7. 100 HG/ML 0.5 HG/HL 
8. 100 HG/HL YES 0.5 HG/HL 
9. 100 HG/HL 
10. 100 HG/HL YES 
.11. 100 HG/ML 0.5 MG/HL 
12. 100 HG/ML YES 0.5 HG/HL 
13. 100 MG/HL 
14. 100 HG/Hl YES 
15. 100 HG/Hl 0.5 MG/HL 
16. 100 HG/Hl YES 0.5 MG/HL 
17. 100 HG/Hl 
18. 100 HG/HL YES 
19. 100 HG/HL 0.5 HG/HL 
TABLE 6 
ASCORBIC ACID fORMULATIONS (AMPULES) 









1.0 HG/HL 5.OHG/Hl 
1.0 HG/HL 5.0 HG/HL 
1.0 HG/HL 5.0 HG/ML 






2S0 U/ML:50 MG/Ml 
2S0 U/Ml:50 MG/Ml 
250 U/ML:SO MG/ML 
250 U/ML:50 MG/Ml 
250 U/ML:50 MG/Hl 
250 U/HL:50 MG/HL 
250 U/ML: SOHG/ML 
250 U/HL:SO MG/ML 
250 U/HL:50 HG/HL 
250 U/HL:50 HG/ML 
m 
t----' 
RUN ASCORBIC H2 
ACID 
20. 100 HG/Hl YES 
21. 100 HG/Hl 
22. 100 HG/Hl YES 
23. 100 HG/Hl 
24. 100 HG/Hl YES 
25. 100 HG/HL 
26. 100 HG/HL YES 
27. 100 HG/Hl 
28. 100 MG/ML YES 
29. 100 HG/HL 
30. 100 HG/HL YES 
31. 100 HG/HL 









TABLE 6 (CONT) 
ASCORBIC ACID' FORHULATIONS (CONT) 
HETABISULFITE ACETYLCYSTEINE THIOUREA 
1.0 HG/Hl 
1.0 HG/Hl 1.0 HG/Hl 
1.0 HG/HL 1.0 HG/Hl 
1.0 HG/HL 1.0 HG/HL 
1.0 HG/Hl 1.0 HG/Hl 
5.0 HG/Hl 1.0 HG/Hl 
5.0 HG/Hl 1.0 MG/ML 
5.0 HG/Ml 1.0 HG/HL 
5.0 HG/HL 1.0 HG/HL 
1.0 MG/HL 5.0 MG/HL 1.0 HG/HL 
1.0 HG/HL 5.0 HG/RL 1.0 MG/ML 
1.0 HG/HL 5.0 HG/Hl 1.0 HG/HL 
1.0 HG/HL 5.0 HG/Hl 1.0 MG/HL 
GLUCOSE OXIOASE:GLUCOSE 
250U/Hl:50 MG/ML 
250 U/Hl:50 HG/Hl 
250 U/HL:50 MG/HL 
250 U/HL:50 HG/HL 
250 u/HL:50 HG/HL 




4.2.3 ASCORBIC ACID BOTTLE FILL EXPERIMENT 
Ascorbic acid solutions were prepared by dissolving 
ascorbic acid crystals in distilled water to make'a stock 
solution containing 100 mg/mL of ascorbic acid. This stock 
solution was then used to make solutions containing the 










Glucose oxidase 250 u/mL 
Glucose· SO mg/mL 
This was done by accurately weighing enough of each 
antioxidant to make a solution four times as concentrated as 
the final solutions and tr~nsferring the antioxidant to a 100 
mL volumetric flask. The antioxidants were then dissolved in 
the ascorbic acid stock solution, and the formulations were 
then prepared by pippetting 25 mL of each antioxidant solution 
into 100 mL volumetrics and mixing with any other antioxidants 
until each formulation was prepared. Glucose oxidase 
solutions were prepared by dissolving the contents of 2 
containers (50,000 u/container) in ascorbic acid stock 
solution in a 100 mL volumetric flask and bringing to volume. 
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All reagants used were A. C. s. reagant grade with the 
exception of glucose oxidase, which was an industrial grade 
provided by Boehringer Mannheim Biochemicals. The 
formulations were then transferred to amber, 4 oz, locktop, 
glass bottles. All volumetric flasks and pippettes used were 
Class A. All reagants used were A. C. s. reagant grade with 
the excpetion of glucose oxidase, which was an -industrial 
grade provided by Boehringer Mannheim Biochemicals. These 
bottle~ were then placed in an incubator (NAPCa) at 45° C and 
periodically sampled. A 5 mL sample was pipetted from each 
bottle at the time of sampling. The samples were diluted in 
a 5% phosphoric acid solution and then assayed by HPLC as 
described in section 4.3.1. 
The concentrations of the antioxidants were based on 
typical concentrations of these antioxidants in pharmaceutical 
products in use today. The glucose oxidase/glucose system 
concentrations were based on preliminary work. The experiment 
was a 2-level factorial and each antioxidant was present at 
the concentration indicated or absent as indicated by the 
factorial shown in section 4.4, Figure 15. 
composition of each run is shown in Table 7. 
The specific 
Run Ascorbic Bisulfite 
Acid 
1 100 mg/lll 
2 100 ag/al 0.5 mg/al 
3 100 mg/lll 
4 100 IIg/ml 0.5 mg/al 
5 100 IBg/lIl 
6 100 mg/ml 0.5 mg/al 
1 100 IIg/ml 0.5 IIlg/al 
8 100 mg/lll 0.5 Dlg/llll 
9 100 IIg/lll 
10 100 mgflll 0.5 mgflll 
11 100 !Dg/Ill 
12 100 IIg/lIl 0.5 Dlg/lil 
13 100 Dlg/ml 
14 100 Dlg/ml 0.5 mg/al 
15 100 mg/lll 
16 100 IIg/lIl 0.5 mg/Ill 
Control 100 mg/al 
Table 7 
Ascorbic Acid Foraul.tions (BottLe ftll) 





1.0 ag/al 5.0 ag/al 





1.0 ag/lll ·5.0 IIg/al 











250 u/~:50 -a/lll 
250 u/al:50 ag/al 
250 u/el:50 ag/ml 
250 u/al:50 ag/ml 
250 u/lll:50 mgfal 
250 u/al:50 ag/al 




4.2.4 MORPHINE AUTOCLAVE EXPERIMENT 
Morphine solutions were prepared by dissolving morphine 
sulfate in distilled water to make a stock solution containing 
3 mg/mL morphine sulfate. This stock solution was then used 
to prepare solutions containing the antioxidants tested at the 
concentrations indicated below: 












antioxidant to make a solution four times as concentrated as 
the final solutions and transferring the antioxidant to a 100 
mL volumetric flask. The antioxidants were then dissolved in 
the ascorbic acid stock solution, and the formulations were 
then prepared by pipeting 25 mL of each antioxidant solution 
into 100 mL volumetrics and mixing with any other antioxidants 
until each formulation was prepared. Glucose oxidase 
solutions were prepared by dissolving the contents of 2 
containers (50,000 u/container) in ascorbic acid stock 
solution in a 100 mL volumetric flask and bringing to volume. 
All volumetric flasks and pipetes used were Class A. All 
reagants used were A. C. s. reagant grade with the exception 
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of glucose oxidase, which was an industrial grade provided by 
Boehringer Mannheim Biochemicals. 
Each antioxidant was present at the level indicated 
above, or absent as dictated by the two-level factorial shown 
in Materials and Methods, section 4.4, Figure 16. The 
specific formulation of each run is shown in Table 8. Each 
stock solution was then used to fill 5 mL, amber, Type '1 
ampules, using a Cozzoli ampul filler. 
The solutions containing nitrogen were made in the same 
way, except nitrogen was bubbled through the the distilled 
water before the addition of morphine, and the stock 
volumetrics were purged with nitrogen before filling, and a 
nitrogen head was put on each volumetric after filling. 
Ampules were purged with nitrogen 'before filling, and nitrogen 
was bubbled through the solutions in each ampul before 
sealing, and a nitrogen head was put on each ampul. Ampules 
were heat sealed using a Cozzoli ampul sealing device. 
The ampules were then placed in a steam autoclave 
(AMSCO) and sterilized at 121°C and 20 lbs/inz. The 
sterilization cycle was 30 minutes. The ampules were then 
removed from the autoclave and assayed by the, HPLC method 
described in the Materials and Methods, Sec. 4.3.2. 
Run Morphine H2 He Bisulfite 
1. 3.0 IIg/lil 
2. 3.0 .gllil Ves 
3. 3.0 IIg/lil 0.5 IIg/lil 
4. 3.0 mgllil Ves 0.5 IIg/lll 
5. 3.0 mg/lll 
6. 3.0 mg/lll Ves 
7. 3.0 mgllil 0.5 mg/lll 
8. 3.0 mg/lll Ves 0.5 IIg/lIl 
9. 3.0 mg/ml 
10. 3.0 mg/lll Yes 
11. 3.0 mg/IIL 0.5 mg/lll 
12. 3.0 mg/IIL Yes 0.5 mg/lll 
13. 3.0 mg/lll 
14. 3.0 IIg/IlL Yes 
15. 3.0 mg/IIL 0.5 IIg/IIL 
16. 3.0 mg/ill Yes 0.5 mg/mL 
Table 8 










5.0 IIg/lIl 1.0 IIg/IiL 
5.0 IIg/IIL 1.0 IIg/IiL 
5.0 ltg/ilL, 1.0 ltg/ilL 




Run Morphine H2 
17. 3.0 mg/mL 
18. 3.0 IIg/lIL Ves 
19. 3.0 Dlg/lIL 
20. 3.0 IIg/ml Ves 
21- 3.0 IIg/lll 
22. 3.0 IIg/mL Ves 
23. 3.0 IIg/mL 
24. 3.0 mg/ill Ves 
25. 3.0 mg/ill 
26. 3.0 mg/al Ves 
27. 3.0 mg/mL 
28. 3.0 mg/llL Ves 
29. 3.0 IIg/llL 
30. 3.0 mg/mL Ves 
31. 3.0 DlgllIL 
32. 3.0 mg/mL Ves 
Teble 8 
Morphine Autoclave Formulations (tont) 





0.5 Rlg/lIL 5.0 molaL 
0.5 IIO/IIL 5.0 IIg/.l 
1.0 MO/IIl 
1.0 MOlal 
0.5 mg/mL 1.0 IIg/al 
0.5 mg/lIl 1.0 IIg/al 
5.0 ag/al 1.0 ag/ml 
5.0 1I0/ml 1.0 I19/I1L 
0.5 mg/llL 5.0 IIg/mL ' 1.0 ag/al 
0.5 mg/mL 5.0 IIg/IlL 1.0 ag/mL 
Glucose Oxidase:Glucose 
250 u/mL:50 ag/al 
250 u/al:50 ~/aL 
250 u/al:50 ~/lIl 
250 u/al:50 ~/al 
250 u/lll:50 ~/al 
250 u/ml:50 ag/aL 
250 u/al:50 ao/al 
250 u/1lL:50 ~/aL 
250 u/lll:50 ~/aL 
250 u/.l:50 MOlal 
250 u/aL:50 ao/al 
250 u/lll:50 MOlal 
250 u/al:50 MOlal 





4.2.5 MORPHINE AMPUL EXPERIMENT 
Morphine solutions were prepared by dissolving morphine 
sulfate (Mallinckrodt, Lot t CBV 386021), in distilled water 
to make a stock solution containing 3 mg/mL morphine sulfate. 
This stock solution was then used to prepare solutions 
containing the antioxidants tested at the concentrations 






5 .. 0 mg/mL 
Thiourea 1.0 mg/mL 
Glucose oxidase 250 u/mL 
Glucose . 50 mg/mL 
This was done by accurately weighing -enough of each 
antioxidant to make a solution four times as concentrated as 
the final solutions and transferring the antioxidant to a 100 
mL volumetric flask. The antioxidants were then dissolved in 
the morphine sulfate stock solution, and the formulations were 
then prepared by pipeting 25 mL of each antioxidant solution 
into 100 mL volumetrics and mixing with any other antioxidants 
until each formulation was prepared. Glucose oxidase 
solutions were prepared by dissolving the contents of 2 
containers (50,000 u/container) ~n ascorbic acid stock 
solution in a 100 mL volumetric flask and bringing to volume. 
All volumetric flasks and pipetes used were Class A. All 
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reagants used were A. C. s. reagant grade with the exception 
of glucose oxidase, which was an industrial grade provided by 
Boehringer Mannheim Biochemicals. 
Each antioxidant was present at the level indicated 
above, or absent as dictated by the two-level factorial shown 
in Materials and .Methods, section 4.4, Figure 17. The 
specific formulation of each run is shown in Table 9. Each 
stock solution was then used to fill 5 mL, amber f Type 1 
ampules (Owens-Illinois), using a Cozzoli ampul filler. 
The solutions containing nitrogen were made in the same 
way, except nitrogen was bubbled through the the distilled 
water before the addition of morphine, and the stock 
volumetrics were purged with nitrogen before filling, and a 
nitrogen head was put on each volumetric after filling. 
Ampules were purged with nitrogen before filling, and nitrogen 
was bubbled through the solutions in each ampul before 
sealing, and a nitrogen head was put on each ampul. Ampules 
were heat sealed using a Cozzoli ampul sealing device. 
The sealed ampuls were then placed in an incubator 
(NAPCO), at 4S·C. Ampules were removed periodically from the 
incubator and assayed by HPLC as described in Methods, Sec. 
4.3.2. 
Run Morphine H2 Bisulfite 
1. 3.0 IIg/IlL 
2. 3.0 mg/mL Yes 
3. 3.0 IIg/IIIL 0.5 IIgII.l 
4. 3.0 mg/Ill Yes 0.5 flg/mL 
5. 3.0 mg/IIL 
6. 3.0 IIg/nal Yes 
7. 3.0 mg/naL 0.5 IRg/mL 
8. 3.0 nag/mL Yes O.S IIg/mL 
9. 3.0 Itg/nal 
10. 3.0 Dlg/naL Yes 
11- 3.0 Dlg/naL 0.5 IIg/mL 
12. 3.0 mg/mL Yes 0.5 IIg/mL 
13. 3.0 mg/mL 
14. 3.0 mg/AIL Yes 
15. 3.0 mg/IIL 0.5 IIg/mL 
16. 3.0 mg/mL Yes 0.5 fig/ilL 
17. 3.0 mg/mL 
18. 3.0 Itg/mL Yes 












1.0Ilg/flL 5.0 flg/flL 
1.0 mg/aL 5.0 IIg/IIL 
1.0 mg/IIL 5.0 ag/.L 






250 u/mL:SO flg/fll 
2S0 u/.L:SO flg/.L 
250 u/mL:50 Mg/ml 
250 u/IIL:SO IIg/IlL 
250 u/IIL:50 flg/flL 
250 u/IIL:SO fig/ilL 
250 u/mL: SOmg/mL 
250 u/mL:50 ag/mL 
250 u/aL:50 flg/aL 
250 u/aL:50 flg/flL 
-....J 
tv 
Run Morphine "2 
20. 3.0 mg/lll Yes 
21. ~.O mg/.l 
22. 3.0 mg/lll Yes 
23. 3.0 mo/lll 
24. 3.0 mg/llll Yes 
25. 3.0 mg/ml 
26. 3.0 mg/ml Yes 
27. 3.0 mg/ml 
28. 3.0 mg/mL Yes 
29. 3.0 mg/ml 
30. 3.0 mg/ml Yes 
31. 3.0 mg/IIL 
32. 3.0 mg/mL Yes 
Morphine 




0.5 RIg/ill 1.0 Iag/al 





0.5 IIg/lll 1.0 mg/al 









5.0 Dlo/al 1.0 ao/al 
5.0 IIQ/al 1.0 ag/ilL 
5.0 mg/aL 1.0 ag/aL 
5.0 molal 1.0 ao/al 
5.0 DlO/lil 1.0 mg/lll 
5.0 IIg/al 1.0 ag/IIL 
5.0 IIg/al 1.0 IIg/lil 
5.0 lAg/ill 1.0 tag/lll 
Glucose. Oxid ... :GLucose 
250 u/ml:50 IIg/~ 
250 u/al:SO ag/al 
250 u/al:50 ag/al 
250 u/aL:50 ao/aL 
250 u/.l:50 molal 




4.2.6 ISOPROTERENOL EXPERIMENT 
Isoproterenol solutions were prepared by dissolving 
isoproterenol hydrochloride (Sigma, Lot i 95F-0324), in 
distilled water to make a stock solution containing 0.2 mg/mL 
of isoproterenol hydrochloride. This stock solution was then 
used to prepare solutions containing the antioxidants tested 











This was done by accurately weighing enough of each 
antioxidant to make a solution four times as concentrated as . -
the final solutions and transferring the antioxidant to a 100 
mL volumetric flask. The antioxidants were then dissolved in 
the morphine sulfate stock solution, and the formulations were 
then prepared by pipeting 25 mL of each antioxidant solution 
into 100 mL volumetrics and mixing with any other antioxidants 
until each formulation was prepared. Glucose oxidase 
solutions were prepared by dissolving the contents of 2 
containers (50,000 u/container) in ascorbic acid stock 
solution in a 100 mL volumetric flask and bringing to volume. 
All volumetric- flasks and pippettes used were Class A.. All 
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reagants used were A. c. s. reagant grade with the excpetion 
of glucose oxidase, which was an industrial grade provided by 
Boehringer Mannheim Biochemicals. 
Each antioxidant was present at the level indicated 
above, or absent, as dictated by the 2-1evel factorial shown 
in Materials and Methods, section 4. 4 , Figure 18 • The 
specific formulation of each run is shown in Table 10 Each 
stock solution was then used to fill S roL, amber, Type 1 
ampuls (Owens-Illinois), using a Cozzoli ampul filler. 
The solutions containing nitrogen were made in the same 
way, except nitrogen was bubbled through the distilled water 
before the addition of isoproterenol, and the stock 
vo1umetrics were purged with nitrogen before filling, and a 
ni trogen head was put in each volumetric after filling. 
AmpuI.es were purged with nitrogen before filling, and nitrogen 
was bubbled through the solutions in each ampul before 
sealing. Ampules were heat sealed, using a Cozzoli ampul 
sealing device. ,All stock solutions were prepared in light 
resistant, red, Class A volumetrics. 
The sealed ampuls were then placed in an incubator at 
4SoC. Ampuls were removed periodically from the incubator and 
assayed by the HPLC assay described in Materials and Methods, 
Section 4.2.3. 
Run Isoproterenol H2 He Bisulfite 
1. 0.2 lIg/al 
2. 0.2 ag/Ill Yes 
3. 0.2 Jag/Ill 0.5 mg/Ill 
4. 0.2 Ilg/ml Ves 0.5 Rag/Ill 
5. 0.2 ag/lIIl 
6. 0.2 mg/Ill Yes 
7. 0.2 mg/Ill 0.5 mg/Ill 
8. 0.2 ltg/ilL Ves 0.5 mg/IlL 
9. 0.2 IIg/lIl 
10. 0 .. 2 ltg/Ill Yes 
11. 0.2 mg/mL 0.5 lIg/ml 
12. 0.2 mg/ml Yes 0.5 IIIg/IiL 
13. 0.2 IIg/IiL 
14. 0.2 mg/IIL Yes 
15. 0.2 lIo/aL 0.5 IIIg/lil 












5.0 ag/IlL 1.0 IIg/lil 
5.0 mg/Ill 1.0 ltg/ilL 
5.0 Ilg/Ill 1.0 ltg/Ill 





Isoproterenol Foraulations (CONT) 
Run Isoproterenol H2 Ha Bisulfite Acetylcysteine Thiourea Glucose Oxidase:Glucose 
17. 0.2 ag/llL 250 u/1lL:50 ag/al 
18. 0.2 IIg/IIL Yes 250 u/aL:50 ag/aL 
19. 0.2 Itg/IlL 0.5 IIg/IIL 250 u/1lL:50 ag/aL 
20. 0.2 IIg/lIL Yes 0.5 IIg/IiL 250 u/1lL:50 ag/aL 
21. 0.2 IIg/llL 5.0 ag/llL 250 u/1lL:50 ag/aL 
22. 0.2 IIg/mL Yes 5.0 IIg/IIL 250 u/1lL:50 ag/aL 
23. 0.2 mg/llL 0.5 MG/ML 5.0 mg/IIL 250 u/1lL:50 IIg/IIL 
24. 0.2 IIg/llL Yes 0.5 MG/ML 5.0 IIg/IIL 250 u/1lL:50 IIg/IIL 
25. 0.2 mg/IIL 1.0 IIg/IIL 250 u/1IL:50 IIg/llL 
26. 0.2 IIg/mL Yes 1.0 ag/aL 250 u/IIL:50 Dlg/IIL 
27. 0.2 mg/llL 0.5 IIg/IIL 1.0 ag/aL 2~0 u/IIL:50 ag/aL 
28. 0.2 mg/mL Yes 0.5 IIg/llL 1.01lg/mL 250 u/IIl:50 ag/llL 
29. 0.2 IIg/llL 5.0 ag/aL 1.01lg/mL 250 u/IIL:50 ag/aL 
30. 0.2 IRg/lIL Yes 5.0 IIg/aL 1.0 ag/llL 250 u/aL:50 IIg/aL 
31. 0.2 IIg/liL 0.5 IIg/IIL 5.0 ag/aL 1.0 ag/llL 250 u/mL:50 IIg/mL 





Assays for each model drug had to be developed to follow 
the degradation of each drug. Assays were developed for 
ascorbic acid, morphine, and isoproterenol. These assays were 
specific for the drug assayed, rather than any degradation 
products. Therefore, each reaction was followed by assaying 
for amount of drug remaining. All chemicals and reagants used 
were A. C. s. reagant grade or U. S. P. with the exception of 
glucose oxidase, which was industrial grade (Grade III) 
provided by Boehringer Mannheim Biochemicals. All were used 
as provided by the manufacturer or dis·tributor .. 
4.3.1 ASCORBIC ACID 
An HPLC assay was developed for. ascorbic acid. The assay 
developed by Wills, Shaw, and Day was used as starting 
point. (133) The final assay conditions are listed below: 
Waters Model 510 Pump 
Waters Model 481 Variable Wave Detector 
'Shimadzu C-R3A Integrator/Recorder 
Rheodyne Injector with 20 ~L loop 
Whatman Partisil ODS-3 25 cm, 10 ~ Column 
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The mobile phase was 0.01 M sodium phosphate (dibasic). The 
pH was adjusted to 3 with sodium hydroxide. The detector 
wavelength used was 245 nm, and the flow rate was 1 mL/min. 
Sample chromatograms are shown in Figure 7. These 
chromatograms demonstrate excellent separation of the 
individual components from ascorbic acid. The first 
chromatogram is glucose oxidase/glucose and ascorbic acid, the 
second is sodium bisulfite and ascorbic acid, the third is 
sodium metabisulfite and ascorbic acid, the fifth is 
acetylcysteine and ascorbic acid. The second peak in each is 
ascorbic acid. The fourth and sixth chro~atograms are 
thiourea (2nd peak) and ascorbic acid (3rd peak) and all 5 
antioxidants and ascorbic acid I respecti vely . The only 
antioxidant giving a reponse is thiourea, which is the 2nd 
peak in chromatograms 4 and 6. There is no interference from 
any component in the system. 
The coefficient of variation of six replicates of a 
standard solution was 0.9%. The linearity of the assay over 
the range of inter'est is shown in Figure 8. The value of R2 
was 100%. 
b '3.C:63 
'b ..... ".' , . .:.."",
b 3.,7 
Figure 7 
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Concentration (mg/ml> 
Linear regression: Ascorbic acid assay 
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4.3.2 MORPHINE ASSAY 
An HPLC assay was developed for morphine. An assay 
developed by Lee was used as the starting point for assay 
development. (.134) The assay conditions used for the 
experiment are listed below: 
waters Model 510 Pump 
waters Model 481 Variable Wave Detector 
Shimadzu C-R3A Integrator/Recorder 
Rheodyne Injector with 20 ~L loop 
Waters Resolve 5 ~ Spherical CIS Column 
The mobile phase was 0.01 M sodium acetate 95%: 
acetonitrile 5% with 1ml triethylamine/L. The pH was adjusted 
to 4 with acetic acid. The detector wavelength was 240 nm, 
and the flow rate was 1 mL/min. 
Sample chromatograms are shown in Figure 9. 
chromatograms demonstrate excellent separation 
These 
of the 
individual components from morphine. Chro~atogram 1 shows 
the separation in the presence of sodium bisulfite. 
Chromatogram 2 is morphine and sodium metabisulfite. 
Chromatogram 3 is morphine and ,acetylcysteine. Chromatogram 
4 is morphine and thiourea. Chromatogram 5 is morphine and 
the glucose oxidase:glucose system, and chromatogram 6 is 
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morphine with no antioxidants. The peak at - ~.5 min is the 
morphine peak. There is no interference in any of the 
systems. 
The coefficient of variation cif six replicates of a 
standard solution was 0.2%. The linearity of the assay over 
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Figure 10 
8 8.1 a.2 8.3 8.4 8.5 
Concentration (mg/ml) 
Linear regression: Morphine sulfate assay 
86 
4.3.3 ISOPROTERENOL ASSAY 
An HPLC assay was developed for isoproterenol. The assay 
4escribed by Nayak.was used as a starting point. (135) The 
final assay conditions are listed below: 
waters Model 510 Pump 
waters Model 481 Variable Wave Detector 
Shimadzu C-R3A Integrator/Recorder 
Rheodyne Injector with 20 ~L loop 
Rainin Microsorb 5 ~ Column 
The mobile phase was 1 % acetic acid I 2.5% methanol. The 
detector wavelength used was.273 nm, and the flow rate was 1 
mL/min. 
Sample chromatograms are shown in Figure 11 and 12. 
These chromatograms demonstrate excellent separation of the 
individual components from isoproterenol. In Figure 11 , 
chromatogram 1 is sodium bisulfite and isoproterenol. The 
peak at 9 .658 min is isoproterenol. Chromatogram 2 is 
acetylcysteine and isoproterenol (10 min). Chromatogram 3 is 
thiourea (1.098 min) and isoproterenol (10.127). 
Chromatogram 1 in Figure 12 is glucose oxidase/glucose 
and isoproterenol. The isoproterenol peak in all three 
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chromatograms is - 1 Omins. Chromatogram 2 is all antioxidants 
and isoproterenol. Chromatogram 3 is isoproterenol without 
any antioxidants. There is no interference from any component 
in 1:he system. 
The coefficient of variation of six replicates of a 
standard solution was 0.7%. The linearity of the assay over 
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Figure 13 
8 8.1 8.2 e.3 8.4 
Concentration (mg/ml) 
Linear regression: Isoproterenol Hel assay 
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4.4 STATISTICS 
All experiments followed two-level factorial design. 
This allowed estimation of main anq two-factor interactions, 
with maximum precision. The two levels were the presence (+) 
or absence (-) of the antioxidant being evaluated. 
Fractional factorials were used initially to reduce 
experiment size to managable levels. This can be justified 
by the fact that estimation redundancy often occurs in data 
from 2k factorials, and many higher order interactions may be 
negligible. Some factors may be without detectable effects at 
all • (13~) Figure 14 shows the pattern used for the ascorbic 
acid ampul experiment. This experiment was a 26•1 design. 
This is a resolution VI design in which no main effect or two-
factor interaction is confounded with any other main effect or 
two-factor interaction. Figure 15 shows the pattern used for 
the ascorbic acid bottle fill experiment. This is a 25- 1 
factorial of resolution V I where no main effects or two-
factor interactions are confounded with any other main or two-
factor interactions. Figure 16 .shows the pattern used for the 
morphine ampul experiment. It is the same as that used for 
the ascorbic acid ampul experiment. Figure 17 shows the 
factorial design for the morphine autoclave experiment. 
Figure 18 shows the factorial design for the isoproterenol 
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Factorial Design for Ascorbic Acid Ampul Experiment 
Blocks: 2 Factors: 6 Runs: 32 
Run Factors 
ABC D E F 
1 - - - -
2 + - - + 
3 + + - - - + 
4 + + - - - -
5 - - + - - + 
6 + - + - - -
7 - + + -
8 + + + - - + 
9 - + - + 
10 + - - +-
11 - + - + 
12 + + - + - + 
13 - - + + 
14 + - + + - + 
15 - + + + - + 
16 + + + + 
17 - - - - + + 
18 + - - - + -
19 - + - - + -
20 + + - - + + 
21 - - + - + -
22 + - + - + + 
23 - + + - + + 
24 + + + - + -
25 - - - + + -
26 + - - + + + 
27 - + - + + + 
28 + + + + 
29 - - + + + + 
30 + - + + + -
31 - + + + + -
32 + + + + + + 
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Figure 15 
Factorial Design for Ascorbic Bottle Fill Experiment 
Blocks: 1 Factors: 5 Runs: 16 
Run Factors 
A B C D E 
1 - - - - + . 
2 + - - - -
3 - + -
4 + + - - + 
5 + - -
6 + - + - + 
7 - + + - + 
8 + + + 
9 - - - + -
10 + - - + + 
11 - + - + + 
12 + + - + -
13 + + + 
14 + - + + -
15 - + + + -
16 + + + + + 
Figure 16 
Factorial Design for Morphine Autoclave Experiment 
Blocks: 4 Factors: 5 Runs: 32 
Run Factors 
ABC D E 
1 - - -
2 + - - - -
3 + + - - -
4 + + - - -
5 - - + 
6 + - + 
7 - + + - -
8 + + + 
9 - + -
10 + - - + -
11 - + - + -
12 + + - + -
13 - - + + 
14 + - + + -
15 - + + + -
16 + + + + -
17 - - - - + 
18 + - - - + 
19 - + - - + 
20 + + - - + 
21 - - + - + 
22 + - + - + 
23 - + + - + 
24 + + + - + 
25 - + + 
26 + - - + + 
27 - + - + + 
28 + + - + + 
29 + + + 
30 + - + + + 
31 - + + + + 
32 + + + + + 
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Figure 17 
Factorial Design for Morphine Ampul Experiment 
Blocks: 2 Factors: 6 Runs: 32 
Run Factors 
ABC D E F 
1 - - - -
2 + - - + 
3 + + - - - + 
4 + + - - - -
5 - - + - - + 
6 + - + - - -
7 + + - - -
8 + + + - - + 
9 - + - + 
10 + - - + 
11 - + - + 
12 + + - + - + 
13 + + - -
14 + - + + - + 
15 - + + + - + 
16 + + + + - -
17 - - - - + + 
18 + - - - + -
19 - + - - + -
20 + + - - + + 
21 - - + - + -
22 + -. + - + + 
23 - + + - + + 
24 + + + - + -
25 - + + -
26 + - - + + + 
27 - + - + + + 
28 + + - + + -
29 + + + + 
30 + - + + + -
31 - + + + + -
32 + + + + + + 
97 
Figure 18 
Factorial Design for Isoproterenol Experiment 
Blocks: 4 Factors: 5 Runs: 32 
Run Factors 
ABC D E 
1 - - -
2 + 
3 + + -
4 + + - - -
5 - - + 
6 + - + 
7 - + + 
8 + + + 
9 - + -
10 + - - + -
11 - +. - + -
12 + + - + -
13 - - + + -
14 + - + + -
15 - + + + -
+6 + + + + -
17 - - - - + 
18 + - - - + 
19 - + - - + 
20 + + - - + 
21 - - + - + 
22 + - + - + 
23 - + + - + 
24 + + + - + 
25 - + + 
26 + - - + + 
27 - + - + + 
28 + + - + + 
29 - - + + + 
30 + - + + + 
31 - + + + + 
32 + + + + + 
Chapter V. Results 
The following data are the results of the experiments 
~erformed as described in Chapter IV. 
5.1 PRELIMINARY STUDIES 
Tables 11 through 15 show the results of the experiments 
run to determine if a glucose oxidase system would remove 
oxygen fast enough to be tenable as an antioxtdant system. 






o 8.62 180 5.29 540 2.31 
10 8.58 195 5.08 600 2.08 
20 8.39 210 4.87 660 1.91 
30 8.12 225 4.68 720 1.78 
40 7.91 240 4.50 780 1.66 
so 7.68 255 4.33 840 1.56 
60 7.46 270 4.16 900 1.47 
70 7.25 285 3.99 1020 1.34 
80 7.03 300 3.85 1140 1.23 
90 6.84 330 3.57 1260 1.14 
100 6064 360 3.33 1380 1.07 
110 6.44 390 3.11 1500 1.02 
·120 6.27 420 2.91 1800 0.89 
135 5.99 450 2.73 2100 0.80 
150 5.73 480 2.58 2400 0.72 
165 5.52 510 2.44 2700 0.67 
Change in oxygen concentration over time: 15 u/mL glucose 
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(X 1999) 
Change in oxygen concentration over time 
Glucose oxidase lSu/ml: Glucose SOmg/ml 
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Table 12 
1~1··.I· . j~\;l:j:.::::. irj~ 
.... :.:. ... £.:': .::::.: .~:<::.'.' .: .... : 
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0 8.51 195 5.62 660 2.47 
10 8.49 210 5.47 720 2.30 
20 8.37 225 5.29 780 2.14 
30 8.22 240 5.11 840 2.02 
40 8.03 255 4.95 900 1.91 
50 7.86 270 4.80 1020 1.73 
60 7.68 285 4.64 1140 1.59 
70 7.48 300 4.50 1260 1.48 
80 7.34 315 4.36 1380 1.34 
90 7.16 330 4.00 1500 1.32 
100 6.9·9 390 3.17 1800 1.17 
120 6.83 420 3.57 2100 1.06 
130 6.68 450 3.39 2400 0 .. 97 
150 6.24 480 3.20 2700 0 .. 89 
165 6.03 540 2.92 3000 0.84 
180 5.84 600 2.68 
Change in oxygen concentration over time: 15 u/mL glucose 
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Change in oxygen concentration over time 
Glucose oxidase lSujml: Glucose 40mg/ml 
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Table 13 
_i.B$·.··.· .. · :::>:-:-::::::;::: : .. 
mi· 
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0 8.50 240 4 .75 1500 0.78 
10 8.48 255 4 .57 1800 0.65 
20 8.37 270 4 .38 2100 0.54 
30 8.20 285 4 .21 2400 0.45 
40 ... 8.03 300 4 .04 2700 0.38 
50 7.84 330 3 .74 3000 0.33 
60 7.65 360 3 .47 3300 0.29 
70 7.45 390 3 .23 3600 0.26 
80 7.27 420 3 .00 3900 0.24 
90 7.08 450 2 .81 4200 0.22 
100 6.89 480 2.62 4500 0.20 
110 6.73 510 2.46 4800 0.19 
·120 6.55 540 2.31 5100 0.18 
135 6.29 600 2.06 5400 0.17 
150 6.05 660 - 1.85 5700 0.17 
165 5.81 720 1.68 6000 0.16 
180 5.58 780 1.54 6300 0.16 
195. 5.36 840 1.43 6600 0.15 
210 5.14 900 1.33 6900 0.14 
225 4.94 1200 0.99 7200 0.14 
Change in oxygen concentration over time: 15 u/mL glucose 
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Change in oxygen concentration over time 
Glucose oxidase'lSu/ml: Glucose SOmg/ml 
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Table 14 
:ci:.;:;' :: . ..;;IlII •• : " ;';:} : H2 M: @ :( Di Ii::< : : :}>): .'~;: z.~...........! ,: <::',?,-",,:_>, ",'" : :;:::';:: ,: " - ,j:"f', _. ,.1:'):: .:' \:::i ii:, :( ;;::.:::; '=0::>:::::" :::':. " '~:; 7~~r,,:<!2< <:: ' , ;:;:::;:':;: , , 
,,,,' 'j:," :::::::::: '-' ,::<:;:,:::::: :;:;-;):::.::::::::;::;:: -<\ rY..~"'''~J:<;: 
0 8. 80 ISO 6.64 660 2.92 
10 8. 80 195 6.42 720 2.70 
20 8. 76 210 6.25 780 2.51 
30 8. 65 225 6.09 840 2.35 
40 8. 53 240 5.90 900 2.20 
50 8. 39 255 5.73 1200 1.67 
60 S. 26 270 5.59 1500 1.33 
70 S. 11 285 5.42 1800 1.11 
SO 7. 96 300 5.30 2100 0.92 
90 7. 82 330 5.00 2400 0.78 
100 7. 68 360 4.72 2700 0.69 
110 -7. 54 390 4.48 3000 0.60 
120 7. 42 420 4.24 3300 0.54 
135 7~ 23 450 4.06 3600 0.48 
150 7. 03 480 3.86 
165 6. 85 540 3.48 
Change in oxygen concentration over time: 15 u/mL glucose 
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(X 1eee) 
Change in oxygen concentration over time 
Glucose oxidase 15u/ml: Glucose 25mg/ml 
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Table 15 
>:-:ii'" .' :-::::::;::- ::::-: "::::::::: :-:\ !:-,:.?::::::»:::<...:, .. : " . '.: 
1I'~!~lj ,1'[.llli!' . ''.j::? i'i:z~ 
. " ::: . : .. :." ~: :.::: ::::;:}:: :::: i:);:;:.:':: .. ;:,>:4.' ::: .. :;: 
::,,: '. .. : .:::;.: :: ::;.: <:::::':-:: .'FE ,. 
0 8.93 180 4.93 540 1.63 
10 8.93 195 4.66 600 1.45 
20 8.78 210 4.40 660 1.31 
30 8.53 225 4.16 720 1.20 
'40 8.25 240 3.92 780 1.11 
50 7.98 255 3.71 840 1.04 
60 7.71 270 3.51 900 0.97 
70 7.43 285 3.34 1200 0.74 
80 7.15 300 3.17 1500 0.58 
90 6.91 330 2.86 1800 0.47 
100 6.66 360 2.58 2100 0.39 
110 -6.40 390 2.37 2400 0.32 
.120 6.17 420 2.17 2700 0.31 
135 5.84 450 2.01 3000 0.24 
150 5.53 480 1.86 3600 0.24 
165 5.22 510 1.74 3900 0.29 
Change in oxygen concentration over time: 15 u/mL glucose 
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Time <seconds) 
(X leee> 
Change in oxygen concentration over time 
Glucose oxidase 15u/ml: Glucose 75mg/ml 
109 
5.2 ASCORBIC ACID EXPERIMENTAL RESULTS 
5.2.1 ASCORBIC ACID AMPUL RESULTS 
Table 16 show the results of the ascorbic acid ampul 
experiment. This experiment was discontinued due to extreme 


















Ascorbic Acid Ampul Results 
Mean of 3 injecti~ns 
100 82 92 
. 
100 77 91 
100 79 85 
100 85 90 
100 90 81 
100 99 87 
100 90 82 · 
100 97 82 
100 80 85 
100 83 92 
• 100 81 86 . 
100 80 78 
100 89 80 
100 97 84 
100 71 78 








































Table 16 (cont) 
Ascorbic Acid Ampul Results 
Mean of 3 injections 
100 81 93 
100 73 96 
100 79 70 
100 81 79 
100 91 80 
100 96 81 
100 85 83 
100 105 86 
100 83 86 
100 78 83 
100 80 81 
100 82 92 
100 73 79 
100 91 89 
100 81 76 



























ASCORBIC ACID BOTTLE EXPERIMENT RESULTS 
Table 17 details the results of the ascorbic acid bottle 
fill experiment. Table 18 shows the analysis of variance of 
these results. Figure 24 is a barchart that compares the 
results of the individual antioxidant effects. 
-Table 17 
Results of Ascorbic Acid Bottle Fill 
Mean of 3 Injections 
:ll[)I""" "i:.;,'lllflllll;ll :--:::::::::::,.;:::". 
1 II !!!2. 99 al9 !! 91 
2 100 98 91 95 95 
3 100 101 89 94 93 
4 100 94 91 .2! !! 
5 100 99 96 86 91 
6 100 93 88 89 83 -
7 100 91 88 93 83 -
8 100 96 97 95 ..!! 
9 100 96 93 86 92 
10 100 94 96 93 87 
11 100 95 99 96 88 
12 100 100 98 104 94 
t 
13 100 94 . 94 89 85 
14 100 98 98- 99 91 
15 100 97 97 94 89 
16 100 97 97 95 89 






Analysis of Variance for Ascorbic Acid 
Source of Sum of Degrees of Mean Square F-ratio 
variation Squares Freedom 
Main Effects .0039449 5 7.88972E-004 1.006 
Sodium .0007788 1 7.78765E-004 .993 
Bisulfite 
Sodium Meta- .0008019 1 8.01883E-004 1.022 
bisulfite 
Acetyl- .0008375 1 8.37543E-004 1.068 
cysteine 
Thiourea .0007979 1 7.97855E-004 1.017 
Glucose .0007288 1 7.28812E-004 .929 
Oxidase 
System 
Residual .0078448 10 7.84485E-004 
Total (corr) .0117897 15 































Percent Ascorbic Acid Remaining 
After 87 Days at 45°C 
Ref = No Antioxidants 
A = Sodium Bisulfite 
B = Sodium Metabisulfite 
C = Acetylcysteine 
D = Thiourea 
E = Glucose Oxidase System 
115 
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5.3 MORPHINE EXPERIMENTAL RESULTS 
5.3.1 MORPHINE AUTOCLAVE EXPERIMENTAL RESULTS 
Table 19 details the results of the morphine autoclave 
experiment. Table 20 shows the estimates of factor effects 
for this experiment. Table 21 is the analysis of variance of 
the results of this experiment. Figure 25 is a barchart 
comparing the main effects of this experiment. 
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Table 19 
Morphine Autoclave Experimental Results 
concentration Remaining: Mean of 3 Injections (mg/ml) 
30 minute sterilization CYcle 
121 • C, 20lbs/in2 
1 2.92 17 2.92 
2 3.04 18 2.67 
3 2.73 19 2.94 
4 2.88 20 3.01 
5 2.70 21 2.77 
6 2.77 22 2.89 
7 3.05 23 2.86 
8 2.89 24 2.87 
9 2.94 25 2.97 
10 3.01 26 2.89 
11 3.01 27 2.81 
12 3.01 28 2.96 
13 3.00 29 3.01 
14 3.04 30 2.97 
15 -3.08 31 2.96 
16 2.93 32 2.81 
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Table 20 
Estimates of Factor Effects for Morphine Autoclave Experiment 
Average 2.91469 E -0.040625 
A -4.375E-3 AE -0.016875 
B 0.015625 BE 6.25E-4 
AB -0.010625 ABE 0.051875 
C -4.375E-3 CE 6.25E-4 
AC -0.028125 ACE 0.034375 
BC 0.021875 BCE -0.073125 
ABC -0.069375 ABCE -0.026875 
D 0.095625 DE -0.039375 
AD -0.015625 ADE 6.875E-3 
BD -0.048125 BDE -0.043125 
ABD -6.875E-3 ABDE -4.375E-3 
CD 0.029375 CDE 4.375E-3 
ACD -0.026875 ACDE -0.044375 
BCD -0.049375 BCDE 0.070625 
ABCD 0.011875 ABeDE -6.25E-4 
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Table 21 
Analysis of Variance for Morphine Autoclave Experiment _ ... ~~ :;.? :):< :::;:;:::: .................. ··'ii .... .. ' }; .... . ........................................... i .. .~"':: : ::.' 'fl:: :'::::{» ,.; .. ::;..~ f':::'L/; 
. ::::" :.: .. .. : :.::,:::':::; : :::';':. 
. , ... ", ' .. : ." . " . ;.:::;.;; 
:::>::::.,;{ 
Main Effects .0886156 5 .0177231 1.313 0.3079 
Nit.r:uycu .0001531 1 .0001531 0.011 0.9176 
. 
Sodium .0019531 1 .0019531 0.145 0.7127 
Bisulfite 
Acetyl- .0001531 1 .0001531 0.011 0.9176 
cysteine 
Thiourea .0731531 1 .0731531 5.417 0.0334 
Glucose .0132031 1 .0132031 0.978 0.3479 
Oxidase 
System 
2-Factor .0531313 10 .0053131 0.393 0.9309 
Interactions 
AB .0009031 1 .0009031 0.067 0.8019 
AC .0063281 1 .0063281 0.469 0.5106 
BC .0038281 1 .0038281 0.283 0.6073 
AD .0019531 1 .0019531 0.145 0.7127 
BD .0185281 1 .0185281 1.372 0.2586 
CD .0069031 1 .0069031 0.511 0.4924 
AE .0022781 1 .0022781 0.169 0.6910 
BE .0000031 1 .0000031 0.000 0.9882 
CE .0000031 1 .0000031 0.000 0.9882 
DE .0124031 1 .0124031 0.919 0.3622 
Residual .2160500 16 .0135031 
Total .3577969 31 
(corr. ) 
o missing values have been excluded. 
Figure 25 
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o Raf" E B c 
Morphine Autoclave Experiments 
Main Effects 
Ref = No Antioxidants 
A = Nitrogen 
B = Sodium Metabisulfite 
C = Acetylcysteine 
0 = Thiourea 
E = Glucose Oxidase 
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5.3.2 MORPHINE EXPERIMENTAL RESULTS 
Table 22 details the results of the morphine ampul 
experiment. Table 23 summarizes the calculated rate constants 
for each experimental run. Table 24 shows the analysis of 
variance for this experiment. Figure 26 is a plot of the log 
of. morphine concentration against time for the run with no 
antioxidants. Figures 27 through 41 are plots of the log of 




















Morphine Sulfate Ampul Experimental Results 
Mean of 3 Injections (rng/ml) 
Day 0 20 41 62 70 112 116 
3.00 2.91 2.75 2.62 2.59 2.44 
3.00 2.85 2.84 2.66 2.89 2.87 
3.00 2.92 2.83 2.80 2.70 2.73 . 
3.00 2.69 2.62 2.33 2.22 2.45 
3.00 2.91 2.76 2.80 2.81 2.79 
3.00 2.62 2.68 2.61 2.74 2.55 
3.00 2.49 2.37 2.20 2.45 2.30 
3.00 2.84 1.88 2.83 2.86 2.77 
3.00 2.95 2.90 2.77 2.56 2.75 
3.00 1.59 1.65 1.53 1.56 1.55 
3.00 2.43 2.55 2.45 2.40 2.38 
3.00 2.86 2.74 1.85 2.80 2.66 
3.00 2.94 2.88 1.75 2.37 2.61 
3.00 2.65 2.94 2.24 2.85 2.66 
3.00 2.91 2.59 2.90 2.91 1.84 



















Table 22 .(cant) 
Morphine Sulfate Ampul Experimental Results 
Mean of 3 Injections (mg/ml) 
Day 0 20 41 62 70 112 116 
3.00 2.92 2.82 2.77 2.74 2.73 
3.00 2.93 2.81 2.5 2.78 2.48 
3.00 2.90 2.79 2.77 2.65 2.49 
3.00 2.87 2.79 2.60 2.82 2.80 
3.00 2.88 2.71 -2.66 2.76 2.81 
3.00 2.12 2.8 2.52 2.69 2.69 
3.00 2.90 2.39 2.73 2.79 2.71 
3.00 2.64 2.62 2.50 2.69 ~.66 
3.00 2.98 2.85 2.57 2.41 2.30 
3.00 2.91 2.81 2.70 2.81 2.85 
3.00 2.82 2.64 2.47 2.18 2.75 
3.00 2.91 2.85 2.68 2.72 2.71 
3.00 2.88 2.75 2.68 2.76 2.56 
3.00 2.88 2.83 2.87 2.82 2.85 
3.00 2.92 2.79 2.78 2.85 2.53 




Calculated Rate Constants 
1 -1.92911E-3 17 -8.84625E-4 
2 -3.36735E-4 18 -1.6678E-3 
3 -9.09296E-3 19 -1.64106E-3 
4 -2.07079E-3 20 -6.26062E-4 
5 -S.71336E-4 21 -5.58386E-4 
6 -1.01632E-3 22 9.29209E-S 
7 -1.88786E-3 23 -6.49S8E-4 
8 -9.50212E-7 24 <-7.45956E-4 
9 -1.0682E-3 2~ -2.7294E-3 
10 -4.44896E-3 26 -5.06743E-4 
11 -1.60252E-3 27 -1.32841E-3 
12 -1.48931E-3 28 -1.00605E-3 
13 -2.14374E-3 29 -1.28562E-3 
14 -9.14852E-4 30 -3.60899E-4 
15 -3.6S575E-3 31 -1.32962E-3 
16 -6.50003E-4 32 -1.44462E-4 
· Table 24 
Analysis of Variance for Morphine Ampul Experiment 
Source of variation Sum of Squares d.f. Mean square 
MAIN EFFECTS 1.03956E-005 6 1.73260E-006 
(A) Nitrogen 3.21644E-006 1 3.21644E-006 
(B)Na Bisulfite 1.88473E-007 1 1.88473E-007 
(C)Na"Metabisulfite 1.34437E-006 1 1.34437E-006 
(D) Acetylcysteine 3.86789E-006 1 3.86789E-006 
(E) Thiourea 1.73924E-006 1 1.73924E-006 
(F) Glucose Oxidase 3.91873E-008 1 3.91873E-008 
2-FACTOR INTERACTIONS 4.12303E-006 5 8.24606E-007 
AB 1.17167E-006 1 1.17167E-006 
AC 1.33559E-006 1 1.33559E-006 
AD 3.77238E-008 1 3.77238E-008 
AE 1.70223E-008 1 1.70223E-008 
AF 1.56103E-006 1 1.5610JE-006 
RESIDUAL 1.64420E-005 20 8.22102E-007 
TOTAL (CORR.) 3.09607~-O05 31 




















































AF ' AC AE AS AD 
Comparison of Two-Factor Effects for Morphine 
after 112 days at 45-C 
REF = No Antioxidants 
A = Nitrogen 
B = Sodium Bisulfite 
C = Sodium Metabisulfite 
0 = Acetylcysteine 
E = Thiourea 











CE OF BF BE BD OE CF EF CD REF BC 
Comparison of T~o-Factor Effects for Morphine 
after 112 days at 45°C 
REF = No Antioxidants 
A = Nitrogen 
B = Sodium Bisulfite 
C = Sodium Metabisulfite 
D = Acetylcysteine 
E = Thiourea 














AF CF EF co BO DE CE OF BF BE Be 
Comparison of Two-Factor Effects for Morphine 
after 112 days at 45·C 
REF = No Antioxidants 
A = Nitrogen 
B = Sodium Bisulfite 
C = Sodium Metabisulfite 
o = Acetylcysteine 
E = Thiourea 
F = Glucose Oxidase 
128 
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5.4 I ts 
es 25 through 56 of the 
e 57 shows s 
58 shows I 
e 59 the this 29 
60 are plots of the log concentration 
61 is a bar chart showing the 
remaining at the end the experiment 

























































































concentration Determined as Mean of 3 Injections 
















Nitrogen and Sodium Bisulfite 
















Nitrogen and Acetylcysteine 
















Nitrogen and Thiourea 














Nitrogen and Glucose oxidase 
















Sodium Bisulfite and Acetylcysteine 
Concentration Determined as Mean of 3 Injections 
















Sodium Bisulfite and Thiourea 
















Glucose oxidase and Sodium Bisulfite 
















Acetylcysteine and Thiourea 
concentration Determined as Mean of 3 Injections 
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Acetylcysteine and Glucose Oxidase 













Thiourea and Glucose Oxidase 
















Nitrogen, Sodium Bisulfite and Acetylcysteine 
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Table 46 151 
Isoproterenol Experiment 
Sodium Bisulfite, Acetylcysteine, and Glucose Oxidase 












Nitrogen, Thiourea, and Glucose oxidase 
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Isoproterenol Experiment 
Nitrogen, Sodium Bisulfite, Acetylcysteine, and Thiourea 









Table 52 157 
Isoproterenol Experiment 
Nitrogen, Sodium Bisulfite, Acetylcysteine, and Glucose 
Oxidase 









Table 53 158 
Isoproterenol Experiment 
Nitrogen, Sodium Bisulfite, Thiourea, and Glucose oxidase 
Concentration Determined as Mean of 3 Injections 
o 0.2000 









Table 54 159 
.Isoproterenol Experiment 
Nitrogen, Acetylcysteine, Thiourea, and Glucose Oxidase 
Concentration Determined as Mean of 3 I~jections 
















Sodium Bisulfite, Acetylcysteine, Thiourea, and Glucose 
Oxidase 















Nitrogen, Sodium Bisulfite, Acetyl cysteine , Thiourea, and 
Glucose oxidase 
concentration Determined as Mean of 3 Injections 
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Table 57 
Run K(D'"1 ) Run K(D-1 ) 
1. -1.44714E-2 17. 1.01922E-4 
2. -2.34639E-3 18. -6.79337E-4 
3. -2.8231SE-3 19. -1.40184E-3 
4. -3.8979E-3 20. -2.20762E-3 
5. -3.27502E-3 21. -4.35642E-3 
6. -3.09519E-3 22. -4.S0558E-3 
7. -4.66035E-3 23. -2.75096E-3 
8. -5.13315E-3 24. -2.7S096E-4 
9. -1.15143E-2 25. -4.1887SE-4 
10. -1.8243E-3 26. -1.19091E-3 
11. -1.8103E-3 27. -9.14913E-4 
12. -2.5357E-4 28. -1.6417SE-3 
13. -3.S0946E-3 29. -3.35222E-3 
14. -3.06304E-3 30. -2.56112E-3 
15. -5.27464E-3 31. -3.84225E-3 
16. -S.47113E-3 32. -3.39968E-3 
Table 58 
Estimates of factor effects 
for Isoproterenol Experiment 
aver = -3.96727E-3 
A - 1.61441E-3 
B - -1.29102E-5 
AB = -1.5729E-3 
C = -1.44886E-S 
AC - -1~16034E-3 
BC = -1.00661E-3 
ABC = 1.70993E-3 
D = -4.22478E-4 
AD - 6.93942E-S 
BD - -6.57701E-4 
ABD = -2.74313E-4 
CD = 7.53128E-4 
ACD = -1.52567E-4 
BCD - 3.01758E-4 
ABCD - -1.10572E-4 
E = 3.12659E-3 
AE = -1.5407E-3 
BE = -5.54408E-4 
ABE - 1.87446E-3 
CE = -2.70S13E-3 
ACE = 2.00553E-3 
BCE = 1.43403E-3 
ABCE = -1.41355E-3 
DE = 9.00002E-4 
ADE = -2.09408E-4 
BDE = 6.56152E-4 
ABDE = -1.03073E-4 
CDE = -2.80712E-4 
ACDE = -9.48919E-6 
BCDE = -8.24599E-4 
ABCOE= ~2.84242E-4 
Blocks: ABeD ABDE 
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Tabl.e 59 
Analysis of Variance for Isoproterenol Experiment 
Source of variation Sum of Squares d.f. Mean square F-ratio Sig. level 
. 
MAIN EFFECTS 8.14280E-005 5 1.62856E-005 1.448 .2609 
(A) Nitrogen 1.79237E-006' 1 1.79237E-006 .159 .6992 
(B) Sodium Bisulfite 2.29374E-009 1 2.29374E-009 .000 .9889 
(C) Acetylcysteine 1.88682E-009 1 1.88682E-009 .000 .9900 
(D) Thiourea 1.22820E-006 1 1.22820E-006 . .109 .7488 
(E) Glucose Oxidase 7.93901E-005 1 7.93901E-005 7.058 .0172 
2-FACTOR INTERACTIONS 1.00581E-004 10 1.00581E-005 .894 .5585 
AB 3.63719E~006 1 3.63719E-006 .323 .5835 . 
AC 5.94306E-007 1 5.94306E-007- .053 .8235 
BC 9.36220E-006 1 9.36220E-006 .832 .3848 
AD 6.84275E-006 1 6.84275E-006 .608 .4550 
BO 4.34702E-006 1 4.34702E-006 .• 386 .5495 
CD 3.44752E-006 1 3.44752E-006 .306 .5933 
AE 3.30615E-006 1 3.30675E-006 .294 .6009 
Source of variation Sum of Squares d.f. Hean square F-ratio Sig. level 
BE 3.22692E-006 1 3.22692E-006 .287 .6052 
CE 6.09220E-005 '1 6.09220E-005 5.416 .0334 
DE 5.13974E-006 1 5.13974E-006 .457 .5158 
RESIDUAL 1.79980E-004 16 1.12487E-005 
TOTAL (CORR.) 3.61988E-004 31 
t-' 

























E A c B o REF 
Comparison of Isoproterenol Main Factor Effects after 81 
days at 450C 
Ref = No Antioxidants 
A = Nitrogen 
B = Sodium Bisulfite 
C = Acetylcysteine 
D - Thiourea 
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Comparison of Isoproterenol Two-Factor Effects after 81 
days at 4SoC 
Ref = No Antioxidants 
A = Nitrogen 
B = Sodium Bisulfite 
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Comparison of Isoproterenol Two-Factor Effects after 81 
days at 45 C 
Ref = No Antioxidants 
A = Nitrogen 
B = Sodium Bisulfite 
C = Acetylcysteine 
o = Thiourea 
E = Glucose Oxidase 
Chapter VI. Discussion 
Many drugs are subject to oxidative degradation, 
especially in aqueous solutions. A great number of drugs are 
formulated in the reduced form (e.g. morphine, epinephrine, 
ascorbic acid), making them particularly susceptible to 
oxidation. These reactions are mediated by free radical 
formation or by molecular oxygen. 
There are a limited number of antioxidants currently used 
in aqueous systems. The most commonly used antioxidants used 
in aqueous systems are shown in Table 60. 
In general, antioxidants are substances which work by 
being more easily oxidized than the agents they are to 
protect. Therefore I in a closed system, (e. g ., an ampul) they 
may consume essentially all the oxygen present, resulting in 
protection of the drug. The other common mechanism of action 
is free radical inhibition. 
since antioxidants act by being more readily oxidized 
than the drug they protect, it should be a relatively simple 
















Theoretically, all that should be necessary, is to pick an 
antioxidant based on the differences in redox potential 
between the drug and the antioxidant. In reality, this 
approach works. sometimes, but in complex pharmaceutical 
formulations, this method does not have a tremendous success 
rate. 
Sulfur dioxide salts, especially sulfite, bisulfite, and 
metabisulfite, are the most commonly used aqueous 
antioxidants. Regardless of the salt added to the solution, 
the antioxidant moiety depends on the final pH of the 
formulation, . and the final concentration of the· salt used. 
Th~ sulfites, while the most common antioxidants in aqueous 
systems, have some distinct drawbacks. The sulfites often 
react with the drugs they are meant to protect, frequently 
resulting in loss of potency (e.g. epinephrine, morphine). 
The safety of the su1fites is also under attack. In 1986, the 
FDA revoked the GRAS status of sulfiting agents for use on 
fruits and vegetables intended to be served or sold raw. It 
also required that the presence of a detectable amount of 
sulfite (10 ppm) in a food, in which the sulfite does not have 
a technical or functional effect, must be declared on the 
label. 
Glucose oxidase has been known since 1926. It is 
prepared from Aspergillus niger. The commercial grade 
203 
contains appreciable amounts of catalase. The presence of 
catalase is an advantage in this proposed use, as can be seen 






-------------------------> 2 C6H,207 
Glucose oxidase has a number of uses. It has GRAS 
status, and is used in a number of food processes. These 
include thedesugaring of egg albumin and whole eggs I the 
removal of oxygen from acid canned foods, preventing oxidative 
deterioration of the food" as well as providing corrosion 
protection to the cans. It has also seen use in canned and 
bottled beverages, again protecting both the flavoring agents, 
and providing corrosion protection to the cans. It is used to 
stabilize both beer and wines. Its ability to remove 
headspace oxygen in beer was compared to metabisulfite in one 
study. Table 61 shows the comparative results. 
Table 61 
02 removal for headspace gas in canned beer 
02 remaining in gas, p.p.m. 
204 
Storage time Enzyme system Metabisulfite 
1 day 943 1280 
1 week 407 1·170 
1 month 346 915 
2 months 152· 544 
3 months 80 194 
6 months 49 160 
205 
6.1 Glucose oxidase prelim~nary Work 
T~bles 11 through 15 and Figures 19 through 23, section 
5.1, demonstrate' that the glucose oxidase system rapidly 
removes oxygen from an aqueous system. Table 13 shows that 
within 1 and 1/2 hours the dissolved oxygen content is less 
than '0.2 ppm, and within. 2 hours is 0.14 ppm. This is 
approaching. the limits of detection of the oxygen probe (0.1 
ppm). Clearly, the glucose oxidase system is very efficient 
at oxygen removal. 
6.2 Ascorbic Acid 
Ascorbic acid was chosen as the first model drug to test 
the effectiveness of the glucose oxidase system as an 
antioxidant, since it is very easily oxidized. Ascorbic acid 
is available as the free acid, C6Ha06 , and sodium ascorbate, 
C6H706Na. It is soluble in water (1 9 in 3 mL), and alcohol (1 
9 in 5 mL), as well as being somewhat soluble in propylene 
gylcol and glycerol. It has two pKa's, pk, = 4.17, and pk
2 
= 





In addition to its nutritional necessity, ascorbic acid 
206 
has technical uses. About one-half the ascorbic acid used 
today is in the food industry. The largest portion is used as 
a technical aid, rather than a nutritional supplement. That 
is, it is used to achieve some improvement in quality, shelf-
life, or processing, irregardless of its vitamin activity. 
Some of these uses have included color protection of meats, 
flour improver in breadmaking, protection of flavors in canned 
drinks, and as a stabilizer in beer. In the pharmaceutical 
industry it has been used as an antioxidant, as well as 
therapeutically. 
Ascorbic acid degrades under both anaerobic and aerobic 
conditions, yielding different decomposition products. Under 
aerobic conditions, ascorbic acid oxidizes to dehydroascorbic 
acid followed by hydrolysis to diketogulonic acid, which is 
then further oxidized to oxalic acid (138,139). Under 
anaerobic conditions, ascorbic acid degradation results in the 
production of xylose, furfural, and carbon dioxide. Finholt 
(140) proposed the following scheme for anaerobic ascorbic 
acid degradation: 
I ;:::::~1 ... J -~'. al,. ~
I .1 
- "" #7\ ' _~ 




"IC~ I  • 
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Lewin (141) detaile~ the degradation of ascorbic acid as shown 
in Figure 64. The initial degradation step is the formation 
of the monodehydro free radical (142,143). 
A number of methods have been used to protec~ ascorbic 
acid from degradation. Many of these methods involve 
formation of a salt or ester of ascorbic acid with or without 
addition of an antioxidant (144,145). Thiourea has also been 
used to protect ascorbic acid from oxidation (146,147). 
Glucose oxidase has been reported to protect ascorbic acid 
from.oxidation "in heat treated strawberry products (148) and 
orange juice concentrate (149). 
It is apparent from Figure 65 that none of the 
antioxidants tested was any better than no antioxidant at all. 
The.analysis of variance (Table 18, section 5.2.2 confirms 
this. 
One note of interest is the fact that carbon dioxide 
production became apparent in some of the bottles by the end 
of the experiment. All of the bottles in which acetyl-
cysteine was present evolved carbon dioxide. Four of the 
bottles containing glucose oxidase also evolved carbon 
dioxide. In the ampul filling experiment which had been 
discontinued, extreme care had to used in removing these 
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B o E o 
Percent Ascorbic Acid Remaining 
After 87 Days at 4S·C 
Ref = No Antioxidants 
A = Sodium Bisulfite 
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C - Acetylcysteine 
0 - Thiourea . 
E = Glucose Oxidase System 
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an attempt to determine the feasibility of autoclavi~g ampules 
filled with ascorbic acid and the various antioxidants of 
interest, virtually all ampules containing glucose oxidase 
exploded during autoclaving. This gas· production would seem 
to indicate that the ascorbic acid was degrading under 
anaerobic conditions. 
6.3 'Morphine experiments 
Morphine has been in use for almost two hundred years' and 
is still an important analgesic today. It is available in a 
number of forms including the free base, C'7H,~03' morphine 
hydrobromide, C17H1~O~· HBr· 2H20, morphine hydrochloride I 
C17H1~03· HCl· 3H20, and morphine sulfate, (C'7H,c}t03)2· H2S04• 5H20. 




Morphine is not very soluble in water with 1 g dis-
solving in 5 L of water at 2S·C, 1 9 in 1075 mL of boiling 
water, and 1 g in 210 mL of ethanol. Most morphine salts are 
much more soluble in water with 1 g dissolving in 1S-20 mL of 
water at 2SoC and freely soluble in boiling water (150). It 
211 
pKa of 9.81 and a pKb of 6.13 at 20°C (151). 
The primary mode of morphine degradation in aqueous 
solution is oxidation. The effects of pH and atmospheric 
oxygen are the most important factors in the oxidation 
reaction. Morphine is most stable at acidic pH. The 
oxidation rate increases rapidly above pH 5.5. Figure 81 
shows the pH rate profile of aqueous morphine solutions in the 
. presence of excess oxygen (152). Aqueous solutions of 
morphine are usually stabilized by addition of antioxidants 
such as sodium bisulfite, sodiUm metabisulfite, sodium 
sulfite, ascorbic acid, and antipyrine, and by ~eplacing t~e 
air in the container with an inert gas(153). It has been 
reported that morphine oxidation ceases when all the 
atmospheric oxygen in the container has been depleted 
(154,155). The degradation scheme of morphine is shown ln 
Figure 66 (156). 
Two experiments were devised to evaluate the 
effe'ctiveness of glucose oxidase in protecting morphine from 
oxidation. The results of these experiments are detailed in 
sections 4.1.3 and 4.1.4. 
Figure 66 
Morphine Degradation Scheme 
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6.3.1 Morphine Autoclave Experiment 
In the autoclave experiment, no differences were clearly 
seen, but the analysis of variance indicated that thiourea did 
differ significantly from the other treatments (based on 
percent morphine remaining). Nitrogen alone provided the best 
protection, but even in this run, some slight discoloration 
was seen. The glucose oxidase system without nitrogen was 
more effective than with nitrogen. It was just as effective 
as sodium bisulfite and nitrogen, the most common method to 
protect morphine in ampuls. The nitrogen and thiourea system 
was the best combinati9n of the two-factor antioxidant 
systems. 
It is not surprising that the glucose oxidase system was 
of limited effectiveness in the autoclave experiment. This is 
because the enzyme is rapidly deactivated above temperatures 
of 60·C. The system is able to remove some of the dissolved 
oxygen from the system, but the temperature in the autoclave 
rises too rapidly for the system to remove all headspace 
oxygen. In all probability, the enzyme is deactivated before 
all the dissolved oxygen is removed.· It does appear from the 
results that a large portion of the dissolved oxygen is 
removed before the system is destroyed. 
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6.3.2 Morphine Ampul Experiment 
In the other morphine experiment, the sealed ampuls were 
placed in an incubator at 4S·C. since six factors were being 
evaluated, this experiment was confounded to make the number 
of runs manageable. The results of this experiment were much 
different than the autoclave experiment. In this experiment 
the only treatment that was statistically different from the 
others was acetyl cysteine . The acetylcysteine system was 
significantly less able to protect morphine from degradation. 
Looking at the rate constants and the graphs of the log 
of concentration versus time, it is clear that the most 
effective system for protecting morphine is the glucose 
oxidase/nitrogen system. Figures 67 through 71 are overlays 
of each antioxidant (in combination with nitrogen) against the 
control. Looking at the glucose oxidase/nitrogen system 
compared to the most effective two-factor combinations, the 
glucose oxidase system is still the best. This is 
illustrated in Figures 72 through 85. It is interesting to 
note i~ particular Figures 72 and 73 which are comparisons of 
nitrogen/bisulfite and nitrogen/metahisulfite. These are the 
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6.4 Isoproterenol Experiment 
Isoproterenol is a highly potent sympathomimetic amine 
that acts almost exclusively on B receptors. It is used as a 
bronchodilator in respiratory disorders and as a cardiac 
stimulant in heart block, cardiogenic shock after myocardial 
infarct, and septicemic shock (157). 
Th7 che~cal formula of isoproterenol is C"H'7N03. Its 
pKa is 8.64. The hydrochloride form was used in this 
experiment (C11H1~03· HeL) • One gram dissolves in" 3ml of water 
and 50ml ethanol(). The structure of isoproterenol is shown 
below: 
OH 
lsoproterenol is highly susceptible to oxidation in sol-
ution, especially at alkaline pH's (158). 
Isoproterenol is typically protected from oxidation by 
packaging in an oxygen-free environment and the addition of 
antioxidants such as sodium bisulfite and metabisulfite, 
acetyl cysteine , thiourea, and sodium EDTA. Isoproterenol 
oxidation occurs much more rapidly at alkaline pH, so the" pH 
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is adjusted to be acidic. 
Table 59 indicates that the only one or two-factor effect 
that is significant is glucose oxidase. There is a dramatic 
difference in the formulation effects for the main variables. 
This is clearly shown by Figure 86. Glucose oxidase stands 
out as the most effective treatment. In contrast, the only 
significant two-factor . interaction is the combination of 
acetylcysteine and glucose oxidase which is not very effective 
at all, (Figures 87 and 88). Figures 89 through 93 show the 
control against each individual antioxidant. Figures 94 
through 97 show glucose oxidase against each of the other 
individual antioxidants. Figure 98 contrasts the control and 
glucose oxidase against nitrogen and sodium bisulfite 
(individually). Figure 99 demonstrates the differences 
between the control and glucose oxidase, against 
acetylcysteine and thiourea. 
Figures 100 through 109 compare glucose oxidase against 
each tWo-factor interaction. Figure 100 compares glucose 
oxidase against the combinations of nitrogen and sodium 
bisulfite. The difference in slope is striking. Glucose 
oxidase is clearly more effective than the most common methods 
of protecting isoproterenol .. This is also shown in Figure 88. 
It is interesting to note that glucose oxidase alone appears 
to be slightly better than the combination of glucose oxidase 
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and nitr?gen (Figure 90). The most puzzling of these 
comparisons is that shown in Figure 92. This is the 
combination of thiourea and sodium bisulfite. This 
combination appears to act synergistically and to be just as 
good as glucose oxidase in protecting isoproterenol. This is 
very surprising in light of the relative ineffectiveness of 
either of these antioxidants alone or in combination with 
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6.5 Comments and Conclusions 
1 • A glucose oxidase system was found to be an 
effective antioxidant system for isoproterenol. 
2. This system was superior to currently used systems 
for protecting isoproterenol. 
3. Combinations of other antioxidants wi th glucose 
oxidase also appeared to be better than current methods of 
protecting isoproterenol, but w~re not statistically better. 
4. The combination of sodium bisulfite and thiourea was 
also effective in protecting isoproterenol. 
5. Glucose oxidase and nitrogen appeared to be most 
effective in pr'otect,ing morphine from oxidation. 
6. Other combinations containing glucose oxidase also 
appeared to be slightly better than nitrogen and sodium' 
bisulfite. None of the combinations were statistically better 
than any other antioxidant system tested. 
7. None of the systems tested were effective in 
protecting ascorbic acid from degradation, but ascorbic acid 
protected by the glucose oxidase system did appear to degrade 
262 
by the anaerobic route described by Finholt(lS9). 
8. It would appear worthwhile to give further study to 
a glucose oxidase system as a pharmaceutical antioxidant. 
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